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SUMMARY 
 
CHARGE association, or syndrome as it is now known, is a condition where a number of 
congenital malformations are non-randomly associated in a recognizable pattern. There are two 
sets of diagnostic criteria for CHARGE syndrome which are in common usage at present (Blake 
et al., 1998; Verloes, 2005). 
The etiology of CHARGE syndrome was unknown. We identified twin girls with CHARGE 
syndrome and a de novo apparently balanced chromosome translocation 
46,XX,t(8;13)(q11.2;q22). By mapping the chromosome translocation breakpoints we found 
that the gene chromodomain-helicase-DNA-binding protein 7 (CHD7) located at 8q12 was 
disrupted in these girls. CHD7 has a genomic length of 188kb with 9000 coding bases over 37 
exons. It has a putative function as a transcription factor which makes it a good candidate gene 
for a condition which affects multiple body systems. 
Concurrently with this study Vissers et al (2004) identified CHD7 as a cause of CHARGE 
syndrome. They found two individuals with CHARGE syndrome with overlapping 
microdeletions detected by array CGH. By sequencing the 9 genes in this region in a cohort of 
17 cases they identified a mutation in CHD7 in 10 cases. 
We ascertained a cohort of 45 patients with a diagnosis of CHARGE syndrome or possible 
CHARGE syndrome by scrutinizing the clinical genetics databases in Glasgow and Sheffield. 
Part of the cohort was accessed by receipt of samples from clinical genetics departments 
elsewhere in the U.K. and in Lisbon. Clinical information was acquired on this cohort either by 
examination and review of the clinical notes by the author or by completion of a proforma by 
the referring clinician. 
Sequencing in this cohort of 45 patients was successful in 43 individuals. We identified 28 
mutations; 16 nonsense, 10 frameshift and 2 splice site mutations. 20 of the mutations were 
ix 
novel, 8 had been reported in other studies. The mutations were found throughout the gene with 
no particular hotspots. No genotype/phenotype correlations were found either in relationship to 
the position of the mutation within the gene or with regards to the type of mutation. 
I have analyzed the phenotype in our cohort and compared it with the cases of CHARGE 
association reported prior to the availability of mutation analysis. I have also compared the 
phenotype in our mutation positive cases with those reported in other studies which were 
mutation-positive.  
We report two individuals with rare findings in CHARGE syndrome; one with a palsy of the 
twelfth cranial nerve reported anecdotally only once before (Blake et al., 2008), and another 
child with a limb reduction defect which has been reported in five other cases (Aramaki et al., 
2006; Asamoah et al.,2004; Van de Laar et al., 2007). 
Our notes review ascertained an incidence of CHARGE syndrome of 1/10,000. 
 
 
1 
INTRODUCTION 
 
The recognition that an association between coloboma and a number of specific 
congenital malformations might constitute a new syndrome was first proposed in 1979 
by Hall (Hall 1979) and independently by Hittner et al (1979). The acronym CHARGE 
was suggested by Pagon et al (1981), using the cardinal features which were thought to 
occur (Coloboma, Heart disease, Atresia of choanae, Retarded growth and 
development and/or central nervous system anomalies, Genital hypoplasia and Ear 
anomalies) (Pagon et al., 1981). These seven features which were found to be 
nonrandomly associated congenital abnormalities were used to devise the diagnostic 
criteria for CHARGE association. The consensus view was that to make a diagnosis of 
CHARGE association an individual should have either: a) Coloboma or choanal atresia 
+ 3 of the other anomalies, or b) Coloboma + choanal atresia + 2 of the other 
anomalies (Pagon et al., 1981). The diagnostic criteria were updated in 1998 (Blake et 
al., 1998) when more importance was placed on the rarer malformations which 
appeared to be more specific to CHARGE association, including these as major 
criteria, whilst more nonspecific malformations were included in the minor criteria. 
These malformations occur commonly in CHARGE association but also occur in other 
malformation syndromes. 
The major criteria are now considered to be coloboma, choanal atresia, characteristic 
ear anomaly and cranial nerve dysfunction. The minor criteria are genital hypoplasia, 
developmental delay, cardiovascular malformations, growth deficiency, orofacial cleft, 
tracheoesophageal fistula (TOF) and a distinctive face (Blake et al., 1998). Diagnosis 
now requires the presence of 4 major or 3 major + 3 minor criteria. 
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A further set of diagnostic criteria has subsequently been suggested by Verloes 
(Verloes 2005). This allows diagnoses of typical, atypical and partial CHARGE 
syndrome to be made. Using Verloes criteria the major criteria are coloboma, choanal 
atresia and hypoplastic semi-circular canals. The minor criteria are rhombencephalic 
dysfunction, hypothalamo-hypophyseal dysfunction, abnormal middle or external ear, 
malformation of mediastinal organs and mental retardation. Using these criteria a 
diagnosis of Typical CHARGE, Partial/ incomplete CHARGE or atypical CHARGE 
can be made as illustrated in table 1 below. 
 
Table 1. Diagnostic Criteria for CHARGE syndrome (Verloes 2005) 
Typical CHARGE 3 major criteria 2/3 major + 2/5 minor criteria 
Partial/ incomplete CHARGE 2/3 major + 1/5 minor criteria  
Atypical CHARGE 2/3 major + 0/5 minor 1/3 major + 3/5 minor criteria 
 
Using these criteria a diagnosis of Typical CHARGE can be made if there are 3 major 
criteria present or 2 major criteria in addition to at least 2 minor criteria. A diagnosis of 
Partial/incomplete CHARGE can be made if there are 2 major criteria and 1 of the 
minor criteria present. A diagnosis of Atypical CHARGE can be made if there are only 
2 major criteria present or 1 major criterion and at least 3 minor criteria. 
 Both Blake’s (Blake et al., 1998) and Verloes’s (Verloes 2005) criteria are in current 
usage. 
A review of over 100 reported cases in the literature is shown in Table 2. This 
illustrates the relative frequencies of the different malformations in reported cases. 
The anomalies which occur in CHARGE association involve disorder in the 
development of the optic vesicle, otic capsule, midline CNS structures and the upper 
pharynx. They are thought to be the result of abnormal differentiation of cephalic 
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mesoderm and ectoderm (otic placode and first branchial cleft). There is believed to be 
abnormal differentiation, migration and survival of neural crest cells. Abnormal 
interactions of neural crest cells (forming the first and second arch) occur with the 
cephalic mesoderm and the developing forebrain and there is concomitant disorder in 
the development of the rhombencephalon from which the neural crest cells have 
migrated. These events take place between the third and ninth weeks of gestation 
(Siebert et al., 1985; Kirby et al., 1990; Lin et al., 1990) 
 
Table 2. Common malformations in CHARGE association and the percentage of 
individuals in which they occur. (Angelman 1961; Edwards et al., 1961; Stool et al., 
1968; Buckfield et al., 1971; James et al., 1974; Ho et al., 1975; Sekhar et al., 1976; 
Sassani et al., 1977; Say et al., 1977; Hall 1979;Hittner et al., 1979; Lillquist et al., 
1980;Davenport et al., 1986; Oley et al., 1988; and Dhooge et al., 1998) 
Malformation Cases  Percentage
Coloboma 83/105 79% 
Heart disease 76/106 72% 
Choanal atresia 53/100 53% 
Retarded growth 74/89 83% 
MR/CNS anomalies 88/100 88% 
Genital hypoplasia 61/86 71% 
Ear anomalies/deafness 94/104 90% 
Micrognathia/cleft palate 37/66 56% 
Facial palsy 46/94 49% 
Swallowing difficulty 27/66 41% 
Tracheoesophageal fistula 4/62 6.5% 
Numerator is the number of individuals found with the malformation, denominator is 
the number examined. MR, mental retardation, CNS, central nervous system 
 
Coloboma 
Coloboma occurs due to failure of fusion of the choroidal fissure along the infero nasal 
aspect of the optic cup and stalk. The colobomata which occur in CHARGE patients 
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may range from the typical iris coloboma without visual impairment to coloboma 
involving the retina and optic disc. Some individuals have anophthalmos. In 
comparison with other individuals with isolated coloboma there are fewer than 
expected iris coloboma (Pagon et al., 1981). The prevalence of isolated coloboma is 
not known. One study found that coloboma and the related structural developmental 
eye defects of microphthalmia and anophthalmia have a combined birth prevalence of 
2.4-3.5/10,000 (Campbell et al., 2002). Cataract and retinal detachment may occur as 
complications of coloboma (Davenport et al.,1986). 
 
Heart Disease 
Heart malformations in CHARGE are often severe. In the review by Lin et al. (1987) 
42% had a conotruncal anomaly and 36% an aortic arch anomaly. Tetralogy of Fallot 
and double outlet right ventricle each occurred in 38% of cases. AVSD is also 
common. PDA is frequently found either alone or in combination with one of the other 
associated cardiac malformations. Aberrant subclavian arteries may also be present. 
Nonconcordance of heart defects may occur in affected sibs (Lin et al., 1987; Cyran et 
al., 1979; Wyse et al., 1993). 
 
Choanal atresia 
Choanal atresia is a malformation where there is persistence of the primitive membrane 
between the posterior nasal passages and the upper pharynx. The result is that air is 
unable to pass through the nose to the pharynx and then to the lungs. Neonates are 
obligate nasal breathers and thus when present, choanal atresia is frequently diagnosed 
soon after birth. The atresia may be bony or membranous, unilateral or bilateral (Pagon 
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et al., 1981). It is caused by failure of the primitive membrane to divide. Figures 1 and 
2 illustrate the anatomical position of the obstruction (Bonafos et al., 2004). 
  
Figure 1 Schematic of bony choanal atresia. A. Lateral view. B. Axial view. c = 
cavum; nf = nasal fossae; ms = maxillary sinus; p = palate; v = vomer; bb = bone 
block. There is a voluminous bone block causing absence of communication between 
the cavum and the nasal fossae 
 
 
Figure 2 Sinusal computerized tomography scan. Axial section, bone window. Total 
right bone choanal atresia 
 
The prevalence of choanal atresia is approximately 0.82/10,000. In 43% of individuals 
this occurs as an isolated anomaly (Harris et al., 1997). A study looking at airway 
obstruction in 30 CHARGE patients found 14 with pharyngomalacia/laryngomalacia or 
Inferior
Superior 
Anterior Medial Lateral 
Anterior 
Posterior 
L R
Poster
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both, 5 with tracheomalacia and 9 with multiple levels of airway obstruction. In total 
67% of individuals had airway obstruction below the choanae (White et al., 2005). 
 
Retarded growth 
The majority of patients with CHARGE have normal birth weight but by six months 
old are below the third centile for weight and length (Pagon et al., 1981; Blake et al., 
1993); many hospital admissions for treatment of congenital anomalies are 
undoubtedly responsible in part. However over 50% of children with CHARGE have 
gastroesophageal reflux, and pharyngeal in-coordination is also common (Blake et al., 
1990, 1993). Both of these make feeding more difficult. Delayed bone age is also a 
frequent finding (Oley et al., 1988). 
 
Retarded development/CNS anomalies 
Initial studies stated that the majority of CHARGE patients have some learning 
disability which ranges from those with an IQ of 80 to profound retardation (Pagon et 
al., 1981). More recent studies show that up to 50% have a good intellectual outcome 
(Raqbi et al., 2003) and that poor outcome is best predicted by the presence of 
extensive bilateral coloboma, microcephaly and the presence of a brain malformation 
(Vervloed et al., 2006). 
CNS anomalies are quite common in CHARGE. A review of 47 patients by Lin et al 
(1990) found a CNS malformation in 55%. Of these 65% were forebrain 
malformations, 42% had arrhinencephaly, 12% holoprosencephaly and 12% other 
forebrain defects. The other 35% had a non-forebrain malformation. The presence of a 
CNS malformation has been significantly correlated with choanal atresia (Lin et al., 
1990). A recent study by Chalouli et al (2005) of 14 patients with CHARGE showed 
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that all had olfactory deficiency and of these half were anosmic. The 9 individuals who 
had MRI studies all had anomalies of the olfactory bulb and/or tract, structures derived 
from the rhinencephalon (Chalouli et al., 2005). This is concordant with Pinto’s study 
where in all 18 individuals in whom it was assessed there was defective smell and 
abnormality of the olfactory bulb. This was also associated with hypogonadotrophic 
hypogonadism (Pinto et al., 2005). 
More than 75% of individuals are thought to have dysfunction of one or more cranial 
nerves (Byerly and Pauli, 1993). White et al (2005) studied 30 patients with CHARGE 
and found 60% had evidence of chronic aspiration with a further 20% with pharyngeal 
dysmotility. This is thought to be due to dysfunction of the 9th and 10th cranial nerves. 
(White et al., 2005) 
 
Genital Hypoplasia 
The microphallus and cryptorchidism that occurs in boys is easier to detect clinically 
than the labial hypoplasia, which may occur in girls. The cause of genital hypoplasia in 
some patients has been found in a number of studies to be due to pituitary or 
hypothalamic dysfunction (Pagon et al., 1981; Davenport et al., 1986; Blake et al., 
1993; Pinto et al., 2005). In a study of 32 individuals with CHARGE Pinto et al. 
(2005) found 19/20 boys had micropenis/cryptorchidism. Of these 7 out of 9 tested 
were found to have low testosterone levels and 3 had growth hormone deficiency. The 
latter was associated with hypoplasia of the anterior pituitary. Treatment with 
testosterone restored normal penis length in 34% of those in whom it was small at 
birth. In addition to the genital anomalies delayed puberty is common (Pinto et al., 
2005). Some girls may have absent vagina, uterus and ovaries (Ragan et al., 1999). 
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Ear anomalies/deafness 
The ears are typically small and wide with reduced height, cup shaped or lop shaped. 
The ear lobes are small or absent. There is a prominent antihelix which may be 
discontinuous with the antitragus and a triangular concha.  
 
 
 
Figure 3. Typical CHARGE ears 
(http://www.chargesyndrome.ca/IntroducingCHARGEbooklet.htm)  
 
Deafness may be both conductive and sensorineural and can be slowly progressive. 
The audiogram has a typical ‘wedge’ shape (Davenport et al., 1986; Thelin et al., 
1986). Conductive hearing loss occurs due to the persistence of middle ear effusions 
and ossicular malformations which may include misshapen footplate of the stapes, 
absent stapedius tendon/muscle and pyramidal process, and a short incus. The ossicular 
chain may be fixed. The oval window is often abnormal/absent and there may be 
osseous obliteration of the round window (Davenport et al., 1986; Dhooge et al., 1998; 
Verloes 2005). Sensorineural hearing loss may be due to semicircular canal or cochlea 
hypoplasia (Collins et al., 2002). Cochlea hypoplasia may affect only the upper turn of 
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the cochlea or be more severe resulting in the Mondini deformity. Anomalies of the 
semicircular canals have been found in more than 80% of those who have been 
scanned (Morgan et al., 1993). Deafness ranges from mild to profound and may be 
asymmetric. The presence of an external ear anomaly is usually associated with 
deafness in that ear (Pagon et al., 1981). 
 
Limb anomalies 
Limb anomalies are not common in CHARGE syndrome. Those, which have been 
reported, include a distal transverse crease which extends between the 2nd and 3rd 
finger web, 2-3 cutaneous syndactyly, tapered fingers, 5th finger clinodactyly and 
camptodactyly with absence of the distal phalanx of the 5th finger in one individual and 
nail hypoplasia, triphalangeal thumb and ectodactyly. There may be limited supination, 
talipes, sandal gap, tibial hemimelia and dimpling (Davenport et al., 1986; Oley et al., 
1988; Meinecke et al., 1989; Prasad et al., 1997; Dhooge et al., 1998; Jongmans et al., 
2006; Sanlaville et al., 2006). 
 
Other anomalies 
Amongst the other anomalies which may occur urological anomalies are quite 
common. Urethral atresia, ureteral reflux, urethrorectal and urethroperineal fistulae 
were reported by Davenport (Davenport et al., 1986). A review of genitourinary 
anomalies found urinary tract anomalies in 42%. These include solitary kidney, 
hydronephrosis, renal hypoplasia and duplex kidneys. Vesicoureteric reflux is also 
common occurring in 44% (Ragan et al., 1999). 
Other rare anomalies include those involving the skeletal system, the endocrine system, 
the gastrointestinal system and the respiratory tract. Skeletal abnormalities include 
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hemivertibrae (Akisu et al., 1998), scoliosis (Oley et al., 1988), 11 or13 rib pairs 
(Pagon et al., 1981; Oley et al., 1988).  Endocrine and immune system abnormalities 
include absent thymus, T cell dysfunction, absent parathyroid gland (Pagon et al., 
1981; Oley et al., 1988), ectopic thyroid/hypothyroid (Oley et al., 1988; Marin et al., 
1991). Absent thymus/thymic hypoplasia may be more common than previously 
thought. Sanlaville found this abnormality in 7/10 individuals at post mortem 
(Sanlaville et al., 2006). Gastrointestinal abnormalities include, omphalacele (Pagon et 
al., 1981; Oley et al., 1988), imperforate anus, accessory spleen (Davenport et al., 
1986), duodenal atresia (Aramaki et al., 2006) and caecal volvulus (Lai and Feng, 
2006). In the respiratory system in addition to choanal atresia, tracheo-, laryngo- and 
bronchomalacia may occur (Hsuch et al., 2004). 
Individuals with CHARGE have a typical facial appearance. The face is square with 
bitemporal narrowing and a flattened nasal tip (Blake et al., 1998). 
The estimated prevalence of CHARGE association is 1/8500-1/10,000 (Blake et al., 
2003; Keller et al., 2000). 
The cause for CHARGE association was unknown.  The majority of cases have been 
sporadic and several different pathogenic mechanisms have been suggested.   Evidence 
supporting a genetic cause includes the isolated reports of multiplex families with 
presumed autosomal dominant (Mitchell et al., 1985) and autosomal recessive 
inheritance (Awrich et al., 1982; Pagon et al., 1981).  There are also several reports of 
concordant monozygotic twin pairs (Farquhar et al., 2002). There is phenotypic 
overlap with some chromosomal syndromes such as partial trisomy 13 and 4p-.  A 
number of single cases with chromosome abnormalities have also been reported with 
features consistent with a diagnosis of CHARGE association to a greater or lesser 
degree.  These include trisomy 18 (Lee et al., 1995), der (9)t(9;13), der(6)t(4;6) 
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(Sanlaville et al., 2002), ring chromosome 14 (Fledelius1996) and a case with a 
balanced translocation t(6;8)(6p8p;6q8q) (Hurst et al., 1991). The finding of many 
different chromosomal rearrangements suggests that the condition is heterogeneous 
with a number of different genetic causes.  
Identifying the causative gene for a syndrome may be attempted in several ways. 
Linkage studies where there are sufficient numbers of affected individuals in families 
to achieve statistical power is one method, however since this requires multiplex 
families this is unsuitable for this condition. Candidate genes can be sequenced in 
affected individuals, although these are difficult to find when the biological basis of a 
condition is unknown. Genome scans can be undertaken with microsatellite markers to 
identify loss of heterozygosity. This is unlikely to be successful unless deletions are a 
significant cause. Comparative genomic hybridization (CGH) can also be used to 
identify small deletions. Other methods which identify genomic copy number changes 
include representational oligonucleotide microarray analysis (Lucito et al., 2003; Sebat 
et al., 2004) and single nucleotide polymorphism oligonucleotide arrays (SNP arrays) 
(Huang et al., 2004). Mapping chromosomal breakpoints in affected individuals with a 
balanced chromosome translocation would also be a strategy. The few families 
affected by CHARGE association are too small to do linkage studies. Three possible 
candidate genes, PAX2, TUPLE1 and SHH have been sequenced in twenty-seven 
individuals with CHARGE. They were thought to be good candidate genes but no 
mutations have been found (Tellier et al., 2000). Another candidate gene, PITX2 
sequenced in twenty-nine patients with CHARGE also revealed no mutations (Martin 
et al., 2002). Genome scans of 10 patients looking for loss of heterozygosity did not 
detect any deletions (Lalani et al., 2003, 2005). CGH of twenty seven individuals 
identified two different chromosomal abnormalities but no regions which were 
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consistently deleted/duplicated (Sanlaville et al., 2002). Mapping the chromosome 
breakpoints in affected individuals with balanced translocations has been a successful 
strategy in identifying genes responsible for a variety of inherited disorders, from 
Duchenne muscular dystrophy (Worton et al., 1984; Ray et al., 1986) to rare sporadic 
genetic syndromes, which are difficult to identify through conventional linkage 
analysis. 
 A study mapping the translocation breakpoint in an individual with a balanced 
translocation involving chromosomes 2 and 7 identified the gene SEMA3E as a 
possible rare cause of CHARGE association (Lalani et al., 2004). Approximately 1/650 
people have a balanced chromosome rearrangement and for the majority this has no 
phenotypic affect. A small percentage will have learning difficulty, congenital 
anomalies or a syndrome in association with their chromosomal rearrangement. If this 
is de novo it is presumed that the rearrangement involves a small deletion or that the 
chromosomal breakpoints disrupt a single gene which causes the phenotype in that 
individual. We identified a monozygotic twin pair with CHARGE association and a de 
novo chromosomal rearrangement 46,XX,t(8;13)(q11.2;q22).  Both girls fully meet the 
diagnostic criteria for CHARGE association/syndrome (Blake et al., 1998). In addition, 
unlike many of the other chromosomal abnormalities described in association with 
CHARGE, which are unique, this rearrangement shared a common breakpoint with a 
previously reported case (Hurst et al., 1991).  
The clinical diagnosis is paramount when using breakpoint mapping as a strategy to 
identify causative genes.   The diagnosis was secure in the twins described and in the 
reported case with the common chromosome 8 breakpoint (Hurst et al., 1991).  
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HYPOTHESIS 
 
The identical twins have CHARGE association due to a de novo chromosome 
translocation. One of the chromosome breakpoints in our probands disrupts a gene 
which causes CHARGE association. 
 
AIMS 
 
1. Map the translocation breakpoints in our probands. 
2. Identify a candidate gene at the breakpoint. 
3. Ascertain incidence and prevalence of individuals with CHARGE association born 
in Greater Glasgow. 
4. Delineate the phenotype of individuals diagnosed with CHARGE. 
5. If a causative gene is identified, to sequence the gene in other affected individuals to 
assess any genotype/phenotype correlations 
 
 
EXPERIMENTAL APPROACH 
 
Parental consent and local ethics approval was obtained for the study. 
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ASCERTAINMENT OF CHARGE PATIENTS 
 
To ascertain individuals with CHARGE association lists of patients were obtained 
from the Genetics Department database for individuals with a diagnosis list of 
CHARGE and conditions which had overlapping features. Di George (tested negative 
for 22q11 deletion), congenital heart disease, optic nerve hypoplasia, developmental 
delay, and multiple congenital anomalies (MCA). 
A list of patients was obtained from Yorkhill Hospital medical coding of all individuals 
presenting in the last 10 years with a code of coloboma, choanal atresia or MCA. 
The hospital notes of all individuals identified above would be reviewed and a 
proforma developed to list clinical features completed. 
All individuals with a diagnosis of CHARGE association/partial CHARGE association 
identified above would be invited for clinical review. They would be invited to take 
part in the study and blood samples would be obtained following written consent. 
 
 
CASE REPORT OF IDENTICAL TWINS WITH A DE NOVO 
CHROMOSOME TRANSLOCATION 
 
The twins were born at 31+6 weeks gestation by normal delivery to healthy unrelated 
parents.  There was no family history of congenital malformations.  Birth weights were 
1390g (10th centile) and 1450g (10th centile) for twins 1 and 2 respectively.  They were 
both intubated at birth for respiratory distress.  Attempts to pass nasogastric tubes were 
unsuccessful.  Choanal atresia was presumed and they were managed with oral airways 
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and gastric tubes.  Once extubated CT scans confirmed bilateral bony and membranous 
occlusion.  The choanae were successfully repaired at two months.  
Both girls were found to have bilateral colobomata of the iris and fundi, with 
significant visual impairment due to retinal and macular involvement 
On examination they both had external ear abnormalities and were subsequently found 
to have sensorineural deafness.  Twin 2 was found to have profound sensorineural 
deafness on the left, with normal hearing on the right.  High definition imaging of the 
ears was not performed but CT scans for the choanal atresia also demonstrated an 
under-aerated, presumably contracted, middle ear cavity and possible abnormities of 
the vestibular aqueducts.  Twin 1 has bilateral profound sensorineural hearing loss with 
thresholds of 70-80db at all frequencies on both sides.  She has the same 
abnormalities reported on CT. 
Single umbilical arteries were noted but renal scans were normal.  Echocardiography 
revealed patent ductus arteriosus requiring surgical ligation.  Twin 2 also had a VSD, 
which required pulmonary banding pending closure.   
They had normal cranial ultrasound scans. 
Both girls had swallowing difficulties and had vomiting necessitating fundoplication. 
Postnatal growth continued to be poor, below the 3rd centile, and both twins had 
significant developmental delay. 
Twin 2 died suddenly at age 8 months.  A post-mortem could not ascertain the cause of 
death.   
Figure 4 shows the facial features and typical external ear abnormalities.  
Karyotype revealed a translocation 46,XX,t(8;13)(q11.2;q22) in both girls but in 
neither of the parents. 
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Figure 4 a) Twin 2 aged 2 months b) Twin 1 aged 2 years showing mildly dysmorphic 
features with laterally extended eyebrows with medial flare and c) A typical CHARGE 
ear, low set, protruding and featureless   
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Materials and Methods: Cytogenetics 
Analysis of the probands chromosomes showed an apparently balanced translocation, 
46,XX, t(8;13)(q11.2;q22) as shown in Figure 5. 
 
Figure 5. Photograph of karyotype of twin 1 showing translocation involving 
chromosomes 8 and 13 with breakpoints at q11.2 and q22 respectively. 
 
Metaphase spreads were prepared from heparinised blood using standard cytogenetic 
techniques and fluorescence in situ hybridization (FISH) was performed with BAC, 
biotin labeled probes to characterize the translocation breakpoints on both 
chromosomes 8 and 13.  The probes were selected using the UCSC and Ensembl 
Human Genome Browsers (http://genome.ucsc.edu/cgi-bin/hgGateway and 
http://www.ensembl.org/) at approximately 1MB intervals within the bands that were 
thought to be involved from the karyotype and extending into the bands on either side. 
The methods used for preparing the probes were as follows:  
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Preparation of BAC probes for FISH: 
100ml of LB broth was prepared by adding two 1.1g tablets of Lennox L Broth 
(Sigma®) to 100ml of MQH2O. 400ml of LB agar was prepared by adding eight 1.68g 
Lennox L agar tablets (Sigma®) to 400ml of MQH2O. Both preparations were 
autoclaved and then left to cool. When the preparations were hand hot 100μl of 
20mg/ml Chloramphenicol was added to the broth and 400μl of 20mg/ml 
Chloramphenicol was added to the agar. The plates were poured and allowed to cool 
for about 30 minutes. The BACs were then streaked on to the plates from the stabs 
using 10μl disposable loops. The plates were then incubated overnight at 370C. The LB 
broth was dispensed into sterile universal containers. Two isolated colonies from each 
plate were picked and placed in the broth. The broth was then incubated overnight at 
370C, 200RPM. Two aliquots were taken from each culture and placed in sterile 
glycerol.  2μl of each glycerol stock was then used to inoculate 2.5ml of the sterile LB 
broth with Chloramphenicol. This preparation was then incubated overnight at 370C, 
200RPM. BAC RP3 491L was cultured using the same method as the other BACs but 
using kanomycin instead of chloramphenicol in the cultures. 
 The DNA from the cultures was then isolated as per the CHORI BACPAC miniprep 
method with solutions supplied with the kit. (http://bacpac.chori.org/bacpacmini.htm) 
Solutions used: 
P1 (filter sterilized, 4oC) 
        50mM Tris, pH 8 
        10 mM EDTA 
        100 ug/ml RNase A 
P2 (filter sterilized, room temp) 
        0.2M NaOH 
        1% SDS 
P3 (autoclaved, 4oC) 
        3M KOAc, pH 5.5 
 
TE Buffer (10mM Tris-HCL, pH8.0, 1mM EDTA pH8.0) 
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 2ml of the BAC culture was pipetted into a 2ml eppendorf tube and spun at 
13,000RPM for 3 minutes at room temperature. The supernatant was aspirated from 
the tube which was then inverted for approximately 30 seconds to allow further drying. 
The final remaining drops were then removed with a micropipette and Kim wipes. 
0.3μl of P1 solution was then added to the tube and vortexed to resuspend the pellet. 
0.3μl of P2 solution was then added to the tube whose contents were mixed by 
inverting it approximately 30 times. It was then left at room temperature for at least 
5minutes. 0.3μl of P3 solution was then added to the tube which was inverted 5 times 
to mix the contents. The tube was then placed on ice for at least 5minutes. The tube 
was then spun at 13,000RPM for 10 minutes at 40C. After transferring the supernatant 
to a fresh tube 0.8μl of ice cold Isopropanol was added and the tube inverted 5 times to 
mix the contents. The tube was then placed on ice for at least 5minutes and then spun 
at 13,000RPM, 40C for 15minutes. After this spin the tube was kept in ice until it was 
ready for the next step. The supernatant was removed from the tube. 0.5μl of 70% 
ethanol which had been filtered at room temperature was added to the tube which was 
then inverted 5 times and spun at 40C for 5minutes. The ethanol was removed and a 
fresh 0.5μl of 70% filtered ethanol was added to the tube inverted 5 times and spun at 
40C for 5minutes.The supernatant was then aspirated from the tube and the pellet was 
allowed to air dry at room temperature. When the pellet had become translucent 40μl 
of TE (pH 8) was added to the tube. This was then allowed to stand for one hour at 
room temperature to allow the pellet to resuspend.  The BAC DNA was then kept 
stored at 40C. 
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Nick translation with biotin: 
Nick translation of the BAC DNA was carried out as follows; 
Solutions used: 
10x dNTP mix 0.2mM each dCTP, dGTP, dTTP 
0.1mM dATP 
0.1mM Biotin-14-ATP 
500mM Tris HCL (pH7.8) 
50mM Magnesium chloride 
100mM 2-mercaptoethanol 
100ug/ml bovine serum albumin) 
 
10x enzyme mix 0.5U/ul DNA Polymerase 1 
0.007U/ul DNase 1 
50 mM Tris-HCL (pH7.5) 
5mM Magnesium chloride 
0.1mM phenylmethylsulphonyl fluoride 
50% glycerol 
100ug/ml bovine serum albumin) 
 
Stop buffer  0.5M EDTA (pH 8.0) 
 
 
 5μl of the 10x dNTP mix, 5μl of the BAC DNA, 35μl of MQH2O, and 5μl of the 10x 
enzyme mix were added together whilst keeping cool on ice. The mixture was then 
vortexed and spun at 15,000RPM for 5 seconds. The mix was then incubated at 150C 
for 90minutes.  5μl of stop buffer was then added followed by 4.6μl of sodium acetate 
pH5 (Sigma S-7899), 1μl of 20mg/ml glycogen (Boehringer Mannheim 901393) and 
122μl of iced ethanol. This mixture was then vortexed, frozen at –720C for 15 minutes 
and then spun at 14,000RPM for 30 minutes at room temperature. The supernatant was 
then aspirated from the preparation, and the pellet was vacuum desiccated for 20 
minutes. 10μl of TE (pH8) was then added to the pellet. This was vortexed and spun 
briefly and then left at room temperature for 2 hours until the pellet had completely 
dissolved. 
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Preparing probe; 
Solutions: 
Hyb Buffer 5ml formamide (Fluka 47670) 50% 
 2ml 50% dextran sulphate  10% 
 0.5ml 20xSSC   1xSSC 
 2.5ml sterile water 
 
20xSSC 3M Sodium chloride 
 0.3M Trisodium citrate 
 made up to 1L with purified water 
 
2x SSC 50ml 20xSSC 
 450ml purified water 
 
70% formamide 35ml formamide (Fluka47670) 
 5ml 20xSSC 
 10ml purified water 
 
50% formamide 25ml formamide (Fluka47670) 
 5ml 20xSSC 
 20ml purified water 
 
Milk wash 25g Marvel 
 400ml distilled water 
 100ml 20xSSC 
 250μl Tween 
 
FITC avidin 2.5μl fluoroscein avidin DCS 
 1ml milk wash 
 
Biotinylated anti-avidin 2.5μl Biotinylated anti-avidin D 
 1ml milk wash 
 
x4SSC with T 250μl Tween 20 
 500ml 4xSSC 
 
Counterstain 30μl of 40μg/ml DAPI 
 150μl citifluor AF1 mountant 
 
 0.5μl of probe DNA, 1μl of total human DNA and 8.5μl of Hyb buffer were added to 
an eppendorf tube. The preparation was vortexed and spun, and then incubated first at 
720C for 5-10minutes and then at 370C for one hour. 
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Metaphase spreads were prepared from heparinised blood using standard cytogenetic 
techniques. The slides were then washed by placing in a series of coplin jars first with 
x2SSC for 2 minutes, then 70% ethanol for 2 minutes, 85% ethanol for 2 minutes and 
100% ethanol for 2 minutes. The slides were allowed to air dry. The chromosome 
spreads were then denatured in 70% formamide at 720C for 2 minutes then put in 70% 
ethanol at –200C for 2 minutes. The ethanol series was repeated and the slides allowed 
to air dry.  5μl of the probe was pipetted onto the slide and covered with a cover slip. 
The cover slip was sealed in place by pipetting cow gum around the edge of the slip. 
The slides were then incubated overnight in a water bath at 370C. The cover slip was 
removed and the slides were then washed twice in 50% formamide at 450C for 5 
minutes. The slides were then washed twice in X2SSC at 450C for 5 minutes. The 
slides were then blocked with milk wash, covered with parafilm and incubated at 370C 
for10 minutes. The parafilm was then removed and 150μl FITC avidin added to the 
slide. This was covered with parafilm and incubated at 370C for 15 minutes. After 
removing the parafilm the slides were then washed twice in x4SSC with T for 5 
minutes at room temperature. 150μl of biotinylated antiavidin was then placed on the 
slide, covered with parafilm and incubate at 370C for 15minutes. The parafilm was 
then removed and the slides were washed twice in x4SSC with T for 5 minutes. 150μl 
FITC avidin was then added to the slide. This was covered with parafilm and incubated 
at 370C for 15 minutes. After removing the parafilm the slides were then washed twice 
in x4SSC with T for 5 minutes at room temperature.  150μl Citifluar and 30μl dapi 
counter stain were then placed on the slide and covered with a cover slip. All probes 
were first applied to control chromosomes to check their approximate locations. 
 ‘Walking’ along the chromosome in this way it was hoped that a single clone would 
be found to span each breakpoint. The sequence of this clone could then be used to 
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make sequential 10kb probes to further refine the breakpoints. The Ensembl Human 
Genome Browsers would be consulted to see if the breakpoints occurred in or near any 
genes which might be good candidates for CHARGE association. The Clones were 
supplied by the MRC Human Genetics Unit, Edinburgh and the Sanger Institute 
Mapping Core group.  DNA was extracted according to the CHORI BACPAC 
Resources miniprep method (http://www.chori.org/bacpac/).  FISH signals were 
visualized using the Cytovision image analysis system (Applied Imaging). 
The sequential 10kb probes were produced by long range PCR (using the LRPCR kit, 
Roche) with primers designed on the PRIMER3 website (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) .The sequence data for the clone spanning the 
breakpoint was provided by the Ensembl Human Genome Browser.  Prior to primer 
design repetitive sequences were masked using RepeatMasker 
(http://www.repeatmasker.org/). The primer sequences were then put through a 
genome blast search using the NCBI human genome browser website. 
(http://genome.ucsc.edu/cgi-bin/hgGateway).  
 
Preparing LRPCR products for probes: 
A 10mM dNTP mix was made up by adding together 300μl of MQH2O,50μl of 
dATP(100mM),50μl of dCTP(100mM),50μl of dGTP(100mM) and 50μl 
dTTP(100mM). This was vortexed, spun and then stored at –200C. 
To make the 8900kb probe 1.75μl of dNTP mix, 1.47μl of each primer, 5μl of buffer 1, 
1μl of genomic or BAC DNA, 0.75μl of enzyme and 38.5μl of MQH2O were mixed 
together on ice. 
To make the probes 14000kb,12000kb, 9800kb, 9850kb, 12269kb, 10.1kb, Fish2, Fish 
3 and 9.1kb, 2.5μl of dNTP(10mM), 1.4μl of each primer, 5μl of buffer 2(buffer 3 for 
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14000kb), 1μl of DNA, 37.8μl  of MQH2O, and 0.75μl enzyme were added together on 
ice. These preparations were then placed in a PCR machine into which the following 
program had been entered: a. 920C for 2 minutes, b. 920C for 10 seconds, c. 650C for 
30 seconds, d. 680C for 8 minutes, e. go to step b 9 times, f. 920C for 10 seconds, g. 
650C for 30 sec, h. 680C for 8 minutes, increasing step h. (elongation time) by 20 
seconds per cycle, i. go to step f.,19 times, j. 680C for 7 minutes, .k. 150C forever. 
The PCR products were then purified using QuickTM 2 PCR Purification Kit (Edge 
Biosystems). 
The DNA for these LRPCR products was quantified by making a 1/100 dilution with 
MQH2O and checking the O.D. reading on a spectrophotometer (Pharmacia Biotech 
GeneQuantRNA/DNA calculator). The O.D. reading was used to calculate the volume 
of PCR product required for 1μg of DNA for use in Nick translation. The LRPCR 
products were labeled by Nick translation using the BioNickTMLabeling System 
(Invitrogen) as described above for labeling the BAC probes but with the volume of 
MQH2O varied to make a total reaction volume of 50μl. When preparing the slides half 
the slide area had probe alone the other half had the probe and the chromosome 8q 
telomere added to aid in identifying the chromosomes. 
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Results 
 
Notes review 
 
230 sets of patient’s notes were identified from the patient lists generated from the 
genetics databases and hospital coding. 177 sets of notes have been reviewed. Seven 
individuals fulfilled the diagnostic criteria for CHARGE association. A further three 
individuals with coloboma + 2 other features and five with choanal atresia + 2 other 
features were included in the clinical review. Eight patients were identified for further 
genetic review as completion of the proforma suggested a likely diagnosis not 
previously recorded. Fifty-seven patients had another known diagnosis 
The birth rate in Glasgow is approximately 10,000/yr; if the incidence of CHARGE 
association were 1/10,000 then we would expect to identify ten patients with CHARGE 
in 10 years. Our data confirms an incidence of 1/10,000 although it may be an under 
estimate as coding only lists the first 6 diagnoses on any hospital admission and not all 
individuals with suspected CHARGE are referred to genetics 
 
 
Cytogenetic results 
 
Giemsa banding of metaphase spreads at 550 band resolution had shown a de novo 
apparently balanced chromosome translocation 46,XX,t(8;13)(q11.2;q22), Figure 5. 
The initial FISH experiments using BAC probes, 137L15, 401H2 and 56A10 showed 
that the chromosome 8 breakpoint was distal to q11.2 as these three probes all 
localized to the derivative chromosome 8. The 242M12 probe localized to 
chromosome 10q and was therefore not of use in the breakpoint analysis.   
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 Walking the chromosome using FISH with mapped BAC  probes refined the 
breakpoints to 8q12.2 and 13q31.1 (Tables 3 & 4, Fig 6-10) 
 
Table 3 Hybridization of Chromosome 8 clones to Twin 1                                                             
                      
 Map Location FISH Result 
Probe Name Band  
 
MB from p 
Telomere 
 
Clone Present 
der( 8) 
Clone Present 
der(13) 
RP11 137L15 q11.21 48.60Mb YES NO 
RP11 401H2 q11.22 52.20Mb YES NO 
RP11 56A10 q12.1 55.82Mb YES NO 
RP11 114M5 q12.1 59.40Mb     YES NO 
RP11 414L17 q12.2 61.40Mb YES NO 
RP11 33I11 q12.2 61.80Mb YES YES 
RP11 35A5 q12.2 61.80Mb NO YES 
RP3   491L6 q12.2 61.83Mb    NO YES 
RP11 317H6 q12.2 62.29Mb NO YES 
RP11 227F6 q12.3 62.40Mb NO YES 
RP11 45K10 q12.3 64.48Mb NO YES 
RP11 115G12 q12.3 65.34Mb NO YES 
RP11 366K18 q13.1 67.12Mb NO YES 
RP11 21C5 q13.3 69.42Mb NO YES 
 
 
Table 4 Hybridization of Chromosome 13 clones to Twin 1       
 Map Location FISH Result                      
Probe name   Band 
MB from p 
Telomere 
Clone Present 
der(8)            
 
Clone Present der(13) 
RP11 370A2 q21.33 67.13Mb NO YES 
RP11 309H15 q22.1 71.56Mb NO YES 
RP11 226E21 q22.3 75.46Mb NO YES 
RP11 421K11 q31.1 79.62Mb NO YES 
RP11 533P8 q31.1 79.83Mb NO YES 
RP11 115N13 q31.1 81.0Mb YES NO 
RP11 464I4 q31.1 81.5Mb YES NO 
RP11 366K1 q31.1 85.3Mb YES NO 
RP11 275J18 q31.2 87.4Mb YES NO 
RP11 388D4 q31.3 88.2Mb YES NO 
RP11 632L2 q31.3 91.4Mb YES NO  
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Figure 6. Hybridization of clone RP11 533P8 to twin 1 shows signals on the derivative 
and normal chromosome 13. 
Figure 7. Hybridization of clone RP11 115N13 to twin 1 showing signals on the 
derivative chromosome 8 and the normal chromosome 13. 
  
 The chromosome 13 breakpoint was resolved to 1.17Mb.  This region contained no 
obvious candidate genes. 
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Figure 8. Hybridization of clone RP11 414L17 to twin 1 showing signals on the 
derivative chromosome 8 and the normal chromosome 8. 
Figure 9. Hybridization of clone RP 3491L6 to twin 1 showing signals on the 
derivative chromosome 13 and normal chromosome 8. 
  Clone RP11 33I11 was found to span the breakpoint on chromosome 8 (Figure 10). 
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Figure 10. Hybridization of clone RP11 33I11 to twin 1 showing signals on both 
derivative chromosomes 8 and 13 and the normal chromosome 8. 
 
 
 
The Ensembl database identifies two genes in this region, Q7Z6C0 (Q66K35) and 
CHD7 (chromodomain-helicase-DNA-binding protein 7).  Clone RP11 414L17, which 
includes most of the sequence for Q7Z6C0, is present only on the derivative 
chromosome 8.  This clone contains CHD7 exons 1 and 2 sequence.  The remainder of 
the CHD7 sequence is present in clone RP11 33I11.  Thus CHD7 was disrupted by the 
translocation. FISH probes produced by long range PCR from sequence data for RP11 
33I11 and CHD7 were then used to do fine mapping of the translocation breakpoint on 
the derivative chromosome 8. Table 5 shows the names of the probes, listed in order 
centromere to telomere, left to right and below the size of the PCR product. A further 
probe 14000kb1, which encompassed 9.1kb, failed to amplify.  
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Probe name FISH3 FISH2 10.1kb 9.1kb 1200KB2 9800KB3 8900KB3 9850KB4 12269KB5 
Product size 
(bp) 
9229 9848 9167 9121 11938 9468 8185 9063 11869 
Table 5. Names of the LRPCR probes and their product sizes 
 
FISH2 failed to hybridize to the metaphase preparations. 10.1kb localized to 
chromosome 8 and the derivative chromosome 8 (See Figure 11). 9.1kb localized to 
both derivative chromosomes (See Figure 12). Probes 12000kb2 and 9800kb3 
localized to the normal 8 and the derivative chromosome 13. Thus the manufactured 
probes using RP11 33I11 sequence data showed that the breakpoint was between exons 
3 and 8 (See Figure 13).   
 
 
 
Figure 11. Hybridization of probe 10.1kb to twin 1 showing signals on the normal 
chromosome 8 and the derivative chromosome 8. 
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Figure 12. Hybridization of probe 9.1kb 
to twin 1 showing signals on the 
derivative chromosome 8 and the 
derivative chromosome 13. 
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Figure 13. a) Schematic showing mapping of chromosome 8 breakpoint. Clones to the 
right of the dotted Line mapped to the der 13 and normal 8. b) Schematic of CHD7 
gene with positions of 10.1 and 9.1kb probes show CHD7 is disrupted between exons 3 
and 8. Short vertical Lines represent exons, chromodomain (ch), SNF2 domain (SNF2) 
and helicase domain (H). 
 
Probe 10.1kb (which spans exon 4 and 5) localizes to both the normal and the 
derivative chromosome 8, and probe 9.1kb (which spans exons 6 and 7) localizes to 
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both derivative chromosomes 8 and 13 and the normal 8. The 9.1kb signal was not 
present on the der (8) in every cell, which would be consistent with the effect of a 
smaller portion of the probe sequence being present on the der (8). These findings 
might suggest that the breakpoint lies within the 9.1kb probe region, but the fact that 
the signal was not present on the der(8) in every cell prevented this from being 
concluded with certainty. 
As the breakpoint mapping had identified that the gene CHD7 was disrupted in our 
probands we then went on to perform sequence analysis of this gene in a cohort of 
patients with a diagnosis of CHARGE syndrome or probable CHARGE. 
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Materials and Methods: Molecular 
Mutation analysis of CHD7 in CHARGE and CHARGE- like cases: 
 
CHD7 has a genomic length of 188kb with 9000 coding bases over 37 exons. The 
DNA sequence data for exons in CHD7 was obtained from the UCSC Human genome 
Browser and ENSEMBL databases (http://genome.ucsc.edu/cgi-bin/hgGateway and 
http://www.ensembl.org/). The files copied from the databases were transformed into 
Word documents with sequence extending at least 50bp to either side of each exon. 
These files then had their repetitive sequences masked by entering the data into 
RepeatMasker (http://www.repeatmasker.org/). The masked files were used to design 
the primers to amplify each exon with the primer 3 website 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer design aimed to 
have the primers at least 20bp outside the reading frame and aiming for a final product 
<500bp in length so that they could be sequenced using 36cm capillary tubing which is 
fitted as standard in our sequencer (ABI 3100). 
Subsequently some primers were redesigned to produce longer fragments to reduce the 
total number of sequencing reactions required. These fragments were sequenced in a 
MegaBACE 1000 (GE Healthcare) using cleanup and sequencing methods 2. 
 
The Primers were ordered from Sigma. On receipt of the primers they were 
resuspended in Xμl of 1x TE pH 8 as per the product sheet to make up a 100μM 
solution (A). The suspension was then vortexed and pulse spun. 25 μl of solution A 
was then added to 475μl of 1xTE pH 8, vortexed and pulse spun to make a 5μM 
working stock (B). The efficacy of each set of primers was first tested on control DNA 
samples with a PCR reaction mix containing 2.5μl each of the forward and reverse 
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primer, 1.5 μl of 1/5 diluted control DNA ,  12.5 μl of Quiagen multiplex PCR mix and 
6 μl of UV treated MQ dH2O . These were run with the following program; denatured 
at 950C for 15 minutes then 34 cycles of 950C  for 45seconds, annealing at 54-650C for 
1 minute and 30 seconds, elongation at 720C for 45 seconds. Subsequent primers were 
designed using UCSC in silico PCR and NGRL SNP checker (by Jaqueline Rice). 
Details for the DNA sequence of the primers, the size of the fragments produced and 
the annealing temperatures used in each PCR reaction are shown in appendix 1. To test 
the success of the PCR reaction the product was run on a test gel as follows: briefly 
vortex and pulse spin PCR product, add 5 μl each product to 1 μl loading mix (LM), 
vortex and pulse spin. This mix was then run on a small 1% agar gel at 80V for 20-25 
minutes with a 100kb ladder (Invitrogen). (The gel consisted of 30ml 1 x TE to which 
0.3g of seagam agarose was added. This was microwaved for approximately 
90seconds, then 2.5μl of Ethidium bromide was added and the gel poured).  The gel 
was then photographed under UV light. The PCR product was then cleaned either 
using Shrimp Alkaline phosphatase or the Ampure system. For the former, 2 μl Shrimp 
Alkaline phosphatase was added to 2 μl of a 1/10 dilution of Exonuclease 1 with 
Exonuclease 1 buffer. This mix was vortexed and spun and added to the PCR reaction, 
vortexed and spun again and run on the SHRIMP program which is: 370C for 30 
minutes, 720C for 15 minutes, and then ramp to 40C. For the Ampure system (AMPure 
PCR Purification (Agencourt Bioscience Corporation) the following method was used: 
15μl of each PCR product was transferred into wells in a 96 well plate. The AMPure 
magnetic particle solution was shaken to resuspend the particles and 27μl was pipetted 
into each well. The plate was covered with a plate seal and vortexed for approximately 
30 seconds. The plate was then incubated at room temperature for 5minutes. The plate 
was then placed onto the SPRIPlate® 96R magnetic plate for 5-10mins. The cleared 
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solution was then aspirated from each well in the reaction plate and discarded. 200μl of 
70% ethanol was then added to each well. This was incubated at room temperature for 
30 seconds. The ethanol was then removed by aspiration and discarded. A second 
aliquot of 200μl of 70% ethanol was added and the rest of this step was repeated. The 
plates were then allowed to air dry for ten to twenty minutes. 40μl of MQH2O was then 
added to each well, the plate was covered with a plate seal and vortexed for 30 
seconds. 
 
The cleaned product was then labeled using either ABI PRISM BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied biosystems) or DYEnamic™ ET Dye Terminator 
Kit (MegaBACE™) 
 
 ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit labeling:  
0.2ml PCR microtubes were labeled with an identifier. To each tube was added 0.5 μl 
of the forward or reverse primer, 1-2 μl of the cleaned product(depending on the 
strength of the band on the test gel), 0.5 μl of ABI Big Dye v3.1, 2 μl of buffer and 5-
6 μl of UV treated MQdH2O(depending on the amount of product used) to make a total 
reaction volume of 10 μl.This mix was pulsed and spun and the BigDye program run: 
The BigDye program consists of 30 cycles of (950C for 10seconds, 50-600C for 
20seconds, 720C for 4 minutes) and then ramp to 40C. The annealing temperatures 
varied according to the PCR annealing temperatures. For example fragment 2B had 
650C PCR annealing temperature and 600C sequencing annealing temperature. 
DYEnamic™ ET Dye Terminator Kit (MegaBACE™) labeling: 
For each reaction 2 μl of DYEnamic ET terminator (MegaBACE) reagent premix, 2 μl 
of dilution buffer as supplied in kit, 1 μl of primer at 3.2 - 5 μM, cleaned PCR product 
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approximately 10ng/100 bases and MQH2O to make the volume up to 10 μl were 
added to a well in a 96 well plate. All reagents were briefly spun to the bottom of the 
wells and then run in a thermal cycler for 40 cycles of (95oCfor 20seconds, 50oC for 15 
seconds, 60oC for 1minute) and then ramp to 4oC. 
 
The labeled product was then cleaned by one of two methods, either method 1if the 
BIGDYE system had been used or method 2 if the Ampure system was used. 
 Sequence cleanup method 1: 
 A fresh 3100 MicroAmp Optical 96-well Reaction Plate and balance plate were 
collected. The plate was labeled with the next plate name for the ABI 3100 sequencer.  
The cleanup solution was made by adding Xμl (X=No of samples (+20) x 5μl) of 
125mM EDTA to Yμl (Y= No of samples (+20) x 60 μl) of 100% EtOH. 65 μl of this 
mixture was added to each microtube of labeled product, mixed and transferred to a 
well in the reaction plate. Sample 1 goes in 1A, sample 2 in 1B, sample 8 in 1H, 
sample 9 in 2A and so on. The plate was then covered with a plate seal. The same 
number of wells in the balance plate were filled with 80μl of water. The balance plate 
was covered with a plate seal. Both plates were then left for 30-60 minutes at room 
temperature. Next the plates were spun in plate holders at 3000xg for 45 minutes at 
100C. The plates were then removed from the centrifuge and the plate holders. The 
plate seals were removed and the plates tipped upside down onto pieces of tissue. 
Keeping the plates upside down they were placed on fresh tissues and gently tapped. 
The plates were then replaced upside down in the centrifuge and pulse spun to 200 x g. 
After removing the plates from the centrifuge 150 μl of 70% EtOH was added to each 
of the sample wells and 150 μl of water added to the corresponding wells in the 
balance plate. The plates were covered with fresh plate seals and then spun at 3000 x g 
38 
for 20minutes at 100C. The plates were then removed from the centrifuge and the plate 
holders. The plate seals were removed and the plates tipped upside down onto pieces of 
tissue. Keeping the plates upside down they were placed on fresh tissues and gently 
tapped. The plates were then replaced upside down in the centrifuge and pulse spun to 
200 x g. The sample plate was then covered with a paper towel and left at room 
temperature to air dry for 30-60minutes. 
10 μl of Hi-Di formamide was then added to each sample well tapping the bottom of 
the plates to get the Hi-Di to the bottom of the wells and remove any bubbles. The 
plate was then covered with a plate septa and wrapped in a paper towel. The plate was 
then left at room temperature for at least 2 hours to allow the pellet to resuspend. The 
plates were then put in the ABI 3100 and the samples run. 
 
Sequence cleanup method 2(CleanSEQ Dye Terminator Removal (Agencourt 
Bioscience Corporation) : 
The CleanSEQ magnetic particle solution was shaken to resuspend the particles. 5μl 
was then pipetted into each sample well in a 96 well plate containing 10μl of the 
sequencing reaction.  70μl of 85% ethanol was then added to each well, the plate was 
covered with a plate seal and vortexed for 30seconds. The plate was then left to 
incubate for three minutes at room temperature. The reaction plate was then placed 
onto the SPRIPlate®96R magnetic plate for three minutes. The supernatant was then 
aspirated from each well and discarded. 100μl of 85% ethanol was then added to each 
well and incubated at room temperature for thirty seconds. The ethanol was then 
aspirated out and discarded. A further 100μl of 85% ethanol was then added to each 
well, incubated at room temperature for thirty seconds. The ethanol was then aspirated 
out and discarded. The plate was then allowed to air dry for ten minutes. 30μl of 
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MQH2O was then added to each well. The reaction plate was placed onto the 
SPRIPlate®96R for three minutes. 15μl of the solution in each well was then 
transferred to a new plate before loading onto the  MEGABACETM Sequencer. 
PCR and sequencing was performed on the 37 coding exons (2-38) which was covered 
by 39 fragments. Once amplified and sequenced the trace was compared to a reference 
trace in Mutation surveyor derived from the NCBI Genbank reference genomic DNA 
(NT_008183) and cDNA (NM_017780.2) 
 
  In silico analysis using existing publications, databases and bioinformatics tools were 
used to assess the significance of any sequence changes which were detected. Where 
possible parental samples were used to assist in determining the likelihood of 
previously unreported sequence changes being pathogenic. 
 
Statistical Analysis 
Statistical comparison of the clinical features found in mutation positive and mutation 
negative individuals were made using the Fisher exact test. This test was used as it 
produces more accurate P values with small sample sizes than the Chi squared test 
(Fisher 1922). 
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Results: Molecular 
One third of the exons were optimized for sequencing using control DNAs. PCR 
conditions for these exons are uniform. See table 6. 4 mutations were identified in 
these exons. See Table 9.  Modifying PCR/sequencing conditions for the remaining 
exons was performed by Jacqueline Rice as detailed in appendix I. MLPA on the 
mutation negative cases was carried out by Jacqueline Rice. 
  
Table 6. Reaction conditions for exons using control DNA  
 
.  Denature  Anneal  Elongation  Cycle 
No. 
Exon 
No. 
Amplicon 
length(bp) 
Temp Time Temp Time Temp Time  
4 485 94 30” 55 30” 72 1’ 37 
6 308 94 30” 55 30” 72 1’ 37 
8 374 94 30” 55 30” 72 1’ 37 
10-11 493 94 30” 55 30” 72 1’ 37 
13 452 94 30” 55 30” 72 1’ 37 
14 382 94 30” 55 30” 72 1’ 37 
15 483 94 30” 55 30” 72 1’ 37 
16 418 94 30” 55 30” 72 1’ 37 
27-28 437 94 30” 55 30” 72 1’ 37 
32 355 94 30” 55 30” 72 1’ 37 
35 451 94 30” 55 30” 72 1’ 37 
 
 
Results: Clinical 
Samples were obtained from 45 individuals. Clinical examination was carried out by 
the author or clinical information was provided by completion of the proforma. The 
clinical details are summarized in table 7. Case reports with clinical photographs of 9 
individuals to illustrate the range of features which can occur in this syndrome are in 
appendix II. In our cohort 20 individuals met the clinical criteria as defined by Blake et 
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al (1998). When Verloes criteria are used 8 individuals had typical CHARGE, 1 partial 
CHARGE and 25 atypical CHARGE, a total of 34. These figures are likely to be an 
under estimate, as those with an atypical diagnosis may really have typical CHARGE 
as the majority of individuals had not had their semicircular canals imaged, nor any 
endocrine studies performed. Despite this all individuals who were diagnosed as 
CHARGE using Blake’s criteria were also diagnosed as at least atypical CHARGE 
using Verloes criteria. 
Table 8 shows the absolute numbers and percentage of individuals in our cohort with 
each of the more common clinical features compared to the previous cases reported in 
the literature. The figures are comparable with the exception of choanal atresia which 
was less common in our cohort (28%vs 53%), genital hypoplasia (42% vs.71%) 
although this is often under reported, and cleft palate (33% vs. 56%). In contrast 
tracheoesophageal fistula was twice as common in our cohort (15% vs. 6.5%). 
Table 8. Percentage of individuals in cohort with each of the more common clinical 
features compared to the previous cases reported 
 
Malformation Literature Cases 
(%) 
This cohort (No 
(%) 
Coloboma 83/105(79% 34/45 (75%) 
Heart disease 76/106(72%) 35/45(75%) 
Choanal atresia 53/100(53%) 13/45(28%) 
Retarded growth 74/89(83%) 30/45(67%) 
MR/CNS anomalies 88/100(88%) 33/45(73%) 
Genital hypoplasia 61/86(71%) 19/45(42%) 
Ear anomalies/deafness 94/104(90%) 37/45(82%) 
Micrognathia/cleft palate 37/66(56%) 15/45(33%) 
Facial palsy 46/94(49%) 17/45(37%) 
Swallowing difficulty 27/66(41%) 15/45(33%) 
Tracheoesophageal fistula 4/62(6.5%) 7/45(15%) 
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Table 7. Clinical details in cohort of 45 individuals in whom a diagnosis of CHARGE syndrome was suspected 
 coloboma CN 
palsy 
characteristic 
ear 
Choanal 
atresia 
Heart 
defect 
Genital 
hypoplasia 
Delay, growth/ 
development 
Orofacial 
cleft 
TOF Hormone 
deficiency 
other mutation 
ZA - vii + - - Small 
uterus/ovaries 
Post/mild palate  hghg Severe b/l mixed hl, 
b/l SCC 
abnormality, 
kyphoscoliosis 
Nonsense 
n 
BA - Vii,viii + - - cryptorchid Post/mod - - ? b/l SCC 
abnormality 
Missense? 
significant 
JB ? - + ? Asd, vsd, 
dysplastic 
pulmonary 
valve, b/l 
superior 
caval vein 
cryptorchid Pre & post - - ? Bronchomalacia 
Talipes 
polymicrogyria 
none 
NB b/l iris,retina & 
optic disc 
?ix,x small - Pda,asd, 
dysplastic 
aortic 
valve 
micropenis Post/mild palate - ? Probable b/l hl Frameshift 
n 
KB - -  L+ asd - mod Bifid 
uvula, 
submucous 
palate 
- ? Otitis media none 
RC b/l 
microphthalmia, 
retina,choroid, 
disc coloboma 
viii + + Avsd,rvot - Post/profound lip - ?  Frameshift 
n 
JC b/l fundus, optic 
disc 
- + - Tof,dorv,v
sd,ps,pda 
Micropenis, 
cryptorchid 
Post/mod - + - Otitis media 
hypocalcaemia 
Nonsense 
pr 
JD b/l choroid, L 
disc 
Ix,x + - pda Micropenis, 
cryptorchid 
Post/mild - - Low 
testosterone 
Hypocalcaemia, 
LSNHL 
Frameshift 
n 
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Table 7. Continued 
 coloboma CN 
palsy 
Characteristic 
ear 
Choanal 
atresia 
Heart 
defect 
Genital 
hypoplasia 
Delay, growth/ 
development 
Orofacial 
cleft 
 TOF Hormone 
deficiency 
other mutation 
ZD 
 
b/l. retinal - - - - Small uterus 
?ovaries 
present 
Post/delay palate - ? u/l snhl 
u/l duplex renal 
collecting system 
Nonsense 
n 
CD b/l retinal Viii,ix,
x 
+ - Vsd/pda - Post/mod - - ? Radial ray defect L 
arm, 
?tracheomalacia 
Nonsense 
n 
CF b/l optic disc - + - Pda, wpw Micropenis, 
cryptorchid 
Post/?mild b/l Cl/p + - Profound b/l snhl, 
otitis media, 
vertebral anomalies 
Frameshift 
n 
BF L choriod R vii + L atresia Pda, pfo,* Hypoplastic 
labia majora 
Post/mild - - ? Severe b/l mixed hl, 
agenesis R kidney 
Nonsense 
n 
RF L optic disc ?vii + L atresia - cryptorchidis
m 
Pre & 
post/mild 
- - hghg Severe b/l snhl, 
facial asymmetry, 
vertebral 
malformation 
Nonsense 
n 
EG1 R iris b/l  retinal R vii, 
?b/l 
ix&x 
+ - Pda,asd - Post/mild - - ? Gord, hl?type Frameshift 
n 
EG2 b/l retinal, L 
iris, 
microphthalmia 
Ix,x + - Pfo,pda, 
asd, Raa 
- Post/severe b/l cl/p - ? b/l snhl 
Otitis media, 
tracheomalacia 
Splice site 
n 
SG Iris - - ?L 
stenosis 
Pulmonary 
atresia & 
vsd 
- -/- Sub 
mucous 
cleft 
- ? Imperforate anus fail 
EH1 R retina Ix,x - - R aortic 
arch 
- -/mild - + - Otitis media, 
preauricular tags, 
facial asymmetry 
none 
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Table 7. Continued 
 coloboma CN 
palsy 
Characteristic 
ear 
Choanal 
atresia 
Heart 
defect 
Genital 
hypoplasia 
Delay, growth/ 
development 
Orofacial 
cleft 
TOF Hormone 
deficiency 
other mutation 
EH2 R retinal ?vii + - Vsd, dorv, 
asd, pda 
- Pre, post/ - - ? Small thymus none 
AH
1 
b/l retinal - + - Tetralogy 
of Fallot 
- -/? - - hypocalcaemia immunodeficiency Missense? 
significant   
AH
2 
R retinal - + - - - Post/mild,mod - + ? Hearing aid none 
KJ ?L optic disc Rvii, 
?ix,x 
+ - Asd/vsd & 
rvot 
- Post/yes - - ?  fail 
EL - - prominent - ps - No/mod - - - Microcephaly 
Malrotation of 
bowel 
none 
TL b/l retinal Vii 
,ix,x 
+ - Asd - Post/mod - - ? Snhl, sleep apnoea Frameshift 
n 
JM1 - viii + - Pda,Vsd, 
coarctation 
- post/mod - - ? Hypoplastic SCCs Nonsense 
n 
CM - Rvii, 
Lviii, 
ix,x 
+ - Asd, vsd, 
pda 
cryptorchid No/mod palate - 
 
? Micrognathia, 
tracheostomy, 
dislocated hip, 
hypoplastic SCCs 
Nonsense 
pr 
LM R iris b/l vi - - Avsd - Pre&post/- - - - Oesophageal 
atresia, abnormal 
thumbs(cannot 
abduct) 
none 
JM2 + ? ? ? Vsd,Pda ? ? ? + ?  Nonsense 
pr 
BM b/l - ? + Pda Micropenis Pre & post/? - + ? Immune deficiency Nonsense 
n 
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Table 7. Continued 
 coloboma CN 
palsy 
Characteristic 
ear 
Choanal 
atresia 
Heart 
defect 
Genital 
hypoplasia 
Delay, growth/ 
development 
Orofacial 
cleft 
TOF Hormone 
deficiency 
other mutation 
RM - - - - CAVSD cryptorchid -/? Cl/p - - Immune deficiency, 
dandy walker 
malformation 
none 
CO L choroid RVII - - pda - Post/moderate - - Hypo-
parathyroid 
hemivertibrae Frameshift 
n 
EP b/l choroid, R 
iris & lens 
Lvii + - Pda,pfo - Post/mod - + ? b/l conductive hl Frameshift 
pr 
JP R iris ? Right anotia u/l 
stenosis 
Tetralogy 
of fallot 
- Pre& post/ 
mild 
- - ? Klippel feil , facial 
asymmetry, 
abnormal SCCs 
none 
LP R iris & retina,L 
microphth 
- protruding + vsd -  - - ? Pyloric stenosis none 
IP-S b/l retinal R vii + - - - ?/? palate - ?  Splice site 
pr 
MR + vii + stenosis + - Pre/? - - ?  none 
JR ?L optic disc - R lop R atresia - cryptorchid -/mod - - - b/l snhl,,otitis 
media, poor balance 
None 
HR b/l retinal 
involving optic 
disc 
L vii + - Asd 
secundum 
- -/mild - - ? L snhl Nonsense 
n 
FS b/l retinal Vi,vii,i
x,x 
+ +R Pda, Asd cryptorchid Pre&post/mild Cl/p - hghg Severe hl ?type, 
hypoplastic SCCs 
Nonsense 
n 
DT - Ix,x + + Pavd,ps, 
asd,pda 
Left 
undescended 
testes 
Post/mild - - Low 
testosterone 
b/l snhl, otitis 
media, pyloric 
stenosis, caecal 
volvulus 
Nonsense, 
pr 
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Table 7. Continued 
 coloboma CN 
palsy 
Characteristic 
ear 
Choanal 
atresia 
Heart defect Genital 
hypoplasia 
Delay, growth/ 
development 
Orofacial 
cleft 
TOF Hormone 
deficiency 
other mutation 
JT retinal ix,x +  unspecified 
,pda 
small ? Cl/p +  b/l hl Nonsense, 
pr 
SW b/l iris & retina ix,x + - Pulmonary 
atresia, vsd 
Hypoplasia 
labia minora 
-/Mod,severe Cl/p - - Microcephaly 
Small kidneys 
Hl ?type 
Nonsense 
pr 
GW - - + - Asd/pavd - Post/mild,mod Palate - ? microcephaly none 
KW b/l retinal & 
optic disc 
?ix,x + Partial 
atresia 
- - Post/mild - - ? Hypoplastic SCCs, 
abnormal malleus 
and incus 
Nonsense 
n 
JW b/l chorioretinal Vi,vii,v
iii,ix,x 
+ - - Cryptorchid, 
micropenis 
Post/mild - - ? Anosmic, 
hypocalcaemia, 
hydronephrosis 
Frameshift 
pr 
LZ R optic disc Lvii + - Pda,pfo,mr - Pre,post/severe - - ? Laryngomalacia, b/l 
snhl 
Frameshift 
n 
b/l = bilateral, CN = cranial nerve, Cl/p = cleft lip and palate, GORD = gastroesophageal reflux, hghg = hypogonadotrophic hypogonadism, hl = 
hearing loss, n = novel, pre = prenatal, post = postnatal, pr = previously reported, SCC = semicircular canal, SN = sensorineural, u/l = unilateral, 
L = left, R = right, + = present, - = absent *anomalous origin of right subclavian artery from descending aortic arch 
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17/20 individuals who met Blake’s criteria were found to have a mutation. A detection 
rate of 85%. The detection rate for those with typical CHARGE was 63% (5/8), partial 
CHARGE 100% (1/1) and atypical CHARGE 88% (22/25). The average detection rate 
when analyzing individuals who met Verloes criteria was 82% (28/34). 
No mutations were identified in individuals who did not have at least atypical 
CHARGE. Two sequence changes of uncertain significance were found. One in an 
individual who met diagnostic criteria and one who did not. This is still undergoing 
evaluation. If one uses only the Blake criteria we would not have tested 11 individuals 
who were found to have a mutation. If one is using Verloes criteria to make decisions 
with regards to mutation analysis it is important to arrange imaging of the semicircular 
canals in individuals who have neither coloboma or choanal atresia. 4 of the 7 in our 
cohort who had semicircular canal hypoplasia (and a mutation) would not have met 
diagnostic criteria with out this investigation. Table 9 delineates the mutations in this 
cohort. . Figure 14 is a schematic illustrating the type of mutation and their position 
within the gene. 28 mutations were identified of which 20 were novel. 8 of the 
mutations had been previously reported in other studies. The majority of the mutations 
were nonsense (16) or frameshift (10) and therefore predicted to cause premature 
truncation of the protein. There were 2 splice site mutations and 2 missense sequence 
changes of uncertain significance.  The mutations are spread throughout the gene 
without any hotspots. 
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Table 9. Results of sequence analysis and MLPA in cohort 
 
Name Sequence/amino acid change N/PR Parental test 
result 
MLPA 
result 
ZA c.484C>T p.Q162X N Not tested  
BA c.7579A>C p.M2527L N Not tested  
JB No mutation  Not tested  
NB c.1528delC p.Q510SfsX54 N Not tested  
KB No mutation  Not tested negative 
RC c. 4337_4340delAAAA p.E1446VfsX14 N Not tested  
JC c.7879C>T p.R2627X PR Not tested  
JD c.4422_4423insA p.E1475RfsX4 N De novo  
ZD c.1474C>T p.Q492X N Not tested  
CD c.1969A>T p.K657X N De novo  
CF c.1505_1508delCTGG p.P502LfsX61 N Not tested  
BF c.2180T>G p.L727X N* Not tested  
RF c.1735C>T p.Q579X N Not tested  
EG1 c.5757_5769delCTATCAGCGCAGC p.A1919AfsX7 N Not tested  
EG2 c.2836-1G>T N* De novo  
EH1 No mutation  N/A  
EH2 No mutation  N/A  
AH1 Sequence change? significance  Not tested  
AH2 No mutation  N/A  
EL No mutation  N/A  
TL c.2627delT p.F877LfsX11 N Not tested  
JM1 c.2839C>T p.R947X N* Not tested  
CM c.3655C>T p.R1219X PR Not tested  
LM No mutation  N/A  
JM2 c.5428C>T p.R1810X PR Not tested  
BM c.2505T>G p.Y835X PR* Not tested  
RM No mutation  N/A  
CO c.4527delT p.F1509LfsX37 N Not tested  
EP c.8962dupG p.D2988GfsX2 N De novo  
JP No mutation  N/A  
LP No mutation  N/A  
IP-S c.5405-17G>A PR De novo  
MR No mutation  N/A  
JR No mutation  N/A negative 
HR c.7282C>T p.R2428X N Not tested  
FS c.7291C>T p.Q2431X N Not tested  
DT c.7252C>T p.R2418X PR Not tested  
JT c.7957C>T p.Arg2653X PR Not tested  
SW c.4015C>T p.R1339X PR Not tested  
GW No mutation  N/A  
KW c.934C>T p.R312X N De novo  
JW c.5961delT p.P1987PfsX2 N De novo  
LZ c.6265_6266ins19 p.E2089AfsX15 N Not tested  
N/A not applicable, N novel, PR previously reported, * found by author 
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Figure 14. Schematic illustrating the types of mutation and their position  in the gene.   nonsense mutation,   frameshift mutation, + splice site, 
c/chromo =chromodomain, SNF2 = SNF2 domain, H = Helicase domain, B = Break domain. Domains drawn using amino acid postions from Pfam 
and NCBI protein accession number NP_060250.2. 
 
chromo C SNF2 H B
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Figure 15. Clinical features 1. Coloboma 
Coloboma were present in 24/28 individuals with a mutation (86%) and 8/13 of those 
who did not have a mutation (61%), (P = 0.113).See figure 15. In those with a mutation 
a coloboma of one eye was present in four cases; both eyes in 19 cases and one did not 
specify details. The iris was affected in only five cases that all also had retinal 
involvement. 
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Figure 16. Clinical features 2. Cranial nerve palsies 
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Cranial nerve palsies were present in 25/27 (93%) of those with mutations. Only 6/13 
(46%) of those with no mutation had a cranial nerve palsy, see figure 16. (P = 0.002).  
In those with a mutation the eighth nerve was most frequently affected with bilateral 
involvement in twelve cases, unilateral left sided involvement in four cases and 
unspecified in four cases. The ninth/tenth cranial nerves were involved in thirteen 
cases. The seventh cranial nerve was involved in twelve cases, one bilateral, five right 
sided, three left sided and four not specified. The sixth nerve was affected in two cases. 
The first and twelfth nerves were affected in one case (the same patient).  
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Figure 17. Clinical features 3. External ear anomalies 
 
 
Figure 17 illustrates the number of individuals with external ear abnormalities in 
relation to the presence of a mutation and its’ type. 13/16 (81%) with a nonsense 
mutation had an external ear abnormality. Three individuals with a nonsense mutation 
are shown as not having an external ear malformation, this is because the external ear 
section of the proforma was not completed in two cases and in the third the ears are 
said to be normal. 9/10 (90%) of individuals with a frameshift mutation had an external 
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ear malformation. Both individuals with a splice site mutation had an external ear 
malformation. Thus an external ear malformation was present in at least 24/28 (86%) 
individuals with a mutation. In comparison only 8/13 (61%) of those without a 
mutation had an external ear malformation. (P = 0.02, calculated using figures from 
complete proforma ie. 24/26 vs. 8/13). The data shows that if an individual does not 
have an external ear malformation then they are unlikely to have a mutation. The ear 
malformation ranged from the typical protruding, simple, cup-shaped ear to very subtle 
abnormalities, absent ear lobe and triangular concha. 
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 Figure 18. Clinical features 4. Choanal atresia. 
 
7/27 (26%) of individuals with a mutation had choanal atresia (in one case with a 
mutation this part of the proforma was not completed). In comparison 5/12 (42%) 0f 
individuals without a mutation had choanal atresia. (P = 0.455).  See figure 18 for a 
comparison of the presence of choanal atresia vs. the type of mutation. The choanal 
atresia was unilateral in three cases, bilateral in one case, and details not specified in 
three cases. 
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Figure 19. Clinical features 5. Heart defects. 
 
Figure 19 shows in histogram form the number of individuals with a heart defect 
plotted with the type of mutation. For all individuals with a mutation where the type of 
heart defect was specified, 16/22 had a complex heart defect and 6 had a single heart 
defect. These single defects comprised 4 PDA and 2 ASD. 
 
Of those with a nonsense mutation and a complex heart defect 9/10 had a PDA, 3 had 
an ASD, 5 a VSD, 3 pulmonary stenosis/atresia, 1 PAVD, 1 DORV and 1 anomalous 
origin of the right subclavian artery and 1 coarctation of the aorta. 
Of those individuals with a frameshift mutation and a complex heart defect 4 had a 
PDA, 2 an ASD, 1 AVSD, 1 RVOT, 1 abnormal aortic valve and 1 mitral 
incompetence. 
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The individual with a splice site mutation had a complex heart defect involving a PDA, 
ASD and a PFO. Table 10 shows the frequency of each of the different types of heart 
defect in our cohort. 
 
Table 10. Heart defects/Vascular anomalies in mutation positive cases 
Type of heart defect present in X% of those 
with mutations 
PDA 64 
ASD 29 
VSD 18 
PS 11 
AVSD 4 
PAVD 4 
DORV 4 
Tetralogy of Fallot 4 
Abnormal aortic valve 4 
Anomalous origin right subclavian artery 4 
Mitral incompetence 4 
 
 
10 cases in our cohort who did not have a mutation had a cardiac defect. 4/9 had a 
complex lesion. Of the 5 with a single defect there was 1 ASD, 1 VSD, 2 AVSD, 1 PS 
and 1 right aortic arch. For those with a complex defect, 3 had an ASD, 2 a VSD, 1 
Tetralogy of Fallot, 1 DORV, 1 PDA, 1 PAVD, 1 dysplastic pulmonary valve and 1 
bilateral superior caval vein.  
 
The 3 individuals who met diagnostic criteria for CHARGE, who had heart defects 
were of the same type as in those who had mutations, 1 VSD, 1 ASD + VSD + 
dysplastic pulmonary valve and 1 Tetralogy of Fallot. 
 
There was no significant difference in the frequency of heart defects between the 
mutation positive and mutation negative individuals, P = 1.0. 
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Figure 20. Clinical features 6.Genital anomalies 
 
 
Figure 20 illustrates that15/27(56%) of individuals with a mutation had genital 
hypoplasia.  Four boys had cryptorchidism, two had micropenis and five had both 
cryptorchidism and micropenis. Two girls had a small uterus, one had hypoplastic labia 
majora and one had hypoplastic labia minora. The true figure for genital hypoplasia is 
likely to be higher as this is underreported in girls. 3/13 (23%) individuals without a 
mutation had genital hypoplasia. Comparing the frequency of genital anomalies in 
mutation positive verses mutation negative cases the P value was 0.09.  Urological 
anomalies were not common in this cohort. One case had agenesis of the right kidney, 
on case had bilateral small kidneys, one case had hydronephrosis and one had 
unilateral renal duplex collecting system. 
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Figure 21. Clinical features 7. Growth retardation 
 
 
22/27(81%) individuals with a mutation had retarded growth vs. 7/13(54%) of those 
without a mutation (see Figure 21), P = 0.128. 
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Figure 22.Clinical features 8. Developmental delay. 
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All 23 individuals with mutations in whom it was commented upon had developmental 
delay, 12 mild, 8 moderate and 3 severe. In those cases without a mutation, 1 had 
normal intelligence, 2 mild delay and 5 moderate delay (See Figure 22), P = 0.26. 
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Figure 23. Clinical features 9. Orofacial cleft 
 
  
We identified mutations in 28 individuals, of these 11 had an orofacial cleft (39%). 
These included one cleft lip, five cleft palate, three cleft lip and palate and two bilateral 
cleft lip and palate. In those cases without a mutation 3/13 had a cleft (23%), P = 0.48.  
Six cases had tracheoesophageal fistula, (21%). 2/13(15%) cases without a mutation 
had this malformation. One patient had pyloric stenosis and a caecal volvulus, 
3/27(11%) had vertebral anomalies. 
The paragraphs above compare the clinical features in those individuals with mutations 
with those without mutations in CHD7.  If one compares the phenotype of individuals 
with nonsense mutations at the start of the gene with those at the end of the gene these 
are not significantly different, see Table 11. This is as expected as the introduction of a 
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premature stop codon will result in nonsense mediated decay of the mRNA and 
haploinsuffiency of the CHD7 protein. 
 
Table 11.Clinical features in individuals with a nonsense mutation in Exon 2 vs. 34/36. 
Clinical feature Mutation in exon 2 Mutations in exons 34/36 
Coloboma 4/5 3/4 
Cranial nerve palsy 4/5 4/4 
Ear anomaly 4/5 4/4 
Choanal atresia 1/5 2/4 
Heart defect 2/5 4/4 
Genital hypoplasia 3/5 3/4 
Delay 5/5 3/4 
Orofacial cleft 2/5 2/4 
TOF 1/5 1/4 
Hormone deficiency 1/5 2/4 
Semicircular canal defect 2 1 
Numerator number of individuals with feature. Denominator number of individuals 
with mutation in the exon. 
 
There is also no phenotypic difference between individuals with frameshift mutations 
in relation to the position of the mutation within the gene. The splice site mutation in 
exon 11 found in EG2 causes deletion of that exon and a frameshift. The splice site 
mutation in exon 26 found in IP-S causes an in frame insertion of five amino acids. 
One might expect him to be more mildly affected but in fact he has typical CHARGE 
syndrome. 
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DISCUSSION 
CHARGE syndrome is a condition of previously unknown etiology.  The majority of 
cases have been sporadic and several different pathogenic mechanisms have been 
suggested.   Evidence supporting a genetic cause includes the isolated reports of 
multiplex families with presumed autosomal dominant (Mitchell et al., 1985) and 
autosomal recessive inheritance (Awrich et al., 1982; Pagon et al., 1981). There are 
also several reports of concordant monozygotic twin pairs (Farquhar et al., 2002). 
There is phenotypic overlap with some chromosomal syndromes such as partial 
trisomy 13 and 4p-.  A number of single cases with chromosome abnormalities have 
also been reported with features consistent with a diagnosis of CHARGE 
syndrome/association to a greater or lesser degree.  These include trisomy 18 (Lee et 
al., 1995), der (9)t(9;13), der(6)t(4;6) (Sanlaville et al., 2002), ring chromosome 14 
(Fledelius, 1996) and a case with a balanced translocation t(6;8)(6p8p;6q8q) (Hurst et 
al., 1991). Genome scans of 10 patients looking for loss of heterozygosity did not 
detect any deletions (Lalani et al., 2003, 2005). CGH of twenty seven individuals 
identified two different chromosomal abnormalities but again no regions which were 
consistently deleted/duplicated (Sanlaville et al., 2002).  Concurrently with this study 
Vissers et al (2004) used array comparative genome hybridization in individuals 
diagnosed with CHARGE and found a deletion overlap in two affected individuals at 
8q12.  They sequenced each of the nine predicted genes in this region in CHARGE 
patients and identified CHD7 mutations in10/17 individuals. CHD7 is a gene with 
previously unknown function. It is a member of a relatively newly described family of 
nine proteins which are evolutionarily conserved. These nine proteins are subdivided 
into three groups (Shur and Benayahu, 2005). CHD7 is one of the third group of 
chromatin remodeling enzymes which includes CHD 6, 8 and 9 that are involved in the 
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control of gene expression through chromatin modification.  They contain two N-
terminal chromodomains (chromatin organization modifier), a central SNF2 related 
helicase/ATPase domain and a DNA binding domain, BRK at the C-terminus.  The 
proteins form part of a complex that is involved in the acetylation of histones.  
Acetylation and methylation of histones is important in controlling the transcriptional 
activity of genes through conformational changes to chromatin (Strahl et al., 2000; 
Brehm et al., 2004). These alterations are made by chromatin modifying complexes.  
Recently the yeast CHD1 has been found to be part of the SLIK chromatin modifying 
complex which interacts with Lys 4 methylated histone H3.  The chromodomain 2 
(CD2) of CHD1 appears to be important in recognizing the substrate.  PSI –Blast 
sequence analysis of CD2 in the Swiss-Prot database identified several proteins with 
significant similarity to CD2 including the second chromodomain in CHD7 (Pray-
Grant et al., 2005). 
The CHD gene family are all thought to control gene expression by chromatin 
modification and hence regulate transcription. 
Expression studies have shown that CHD7 is expressed in immune, nervous, muscle, 
secretory and other tissues (GeneCards). The gene is 188Kb in length with 38exons. 
The start codon is in exon 2. 
Following the identification of mutations in CHD7 as a major cause of CHARGE 
syndrome further expression studies have been carried out. Bosman et al (2005) 
sequenced Chd7 on Mouse chromosome 4 in Whirligig mice who have truncations of 
the lateral semicircular canal. 9 mutations were identified. Analysis of the coding 
sequence and protein of mouse Chd7 was found to have very high identity and 
similarity to human CHD7 (94.9 and 97% respectively). Like CHD7 it has two 
chromodomains which are involved in binding to methylated histones at the N-
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terminus, a central SNF2-like ATPase and helicase domains thought to be involved in 
DNA unwinding and two C-terminal domains SANT involved in binding to histone tail 
and BRK involved in DNA binding. Expression studies in mice found that Chd7 is 
expressed in the organs affected in CHARGE syndrome patients, that is eye, olfactory 
epithelium, ear, kidney and vascular system. Expression is widespread during foetal 
development with high expression levels in several epithelial cell types (olfactory, lung 
and gut), the vestibulo-cochlear, facial, olfactory and dorsal root ganglia and several 
specific areas in the brain. There was lower expression in mesenchymal cell types 
(Bosman et al., 2005). Lalani et al (2005) also found Chd7 was widely expressed with 
higher expression in cardiac outflow tract, truncus arteriosus, facio-acoustic 
preganglionic complex, hindbrain, forebrain, mandibular component of first branchial 
arch, otic vesicle, optic stalk, optic vesicle and olfactory pit. Microarray expression 
studies comparing mutation positive individuals with mutation negative individuals 
showed significant differences in CHD7 levels (Lalani et al., 2005), suggesting that 
mutation negative individuals have a different etiology for their malformations. 
Expression studies in human embryos show that at d20-24 CHD7 is ubiquitously 
expressed with distinct signal in the neural tube, by d26 it is expressed throughout the 
central nervous system and neural crest mesenchyme of the pharyngeal arches. By d33 
it is expressed in the cephalic mesenchyme, pharyngeal arches, brain, otic vesicle and 
limb bud mesenchyme with a more intense signal in the spinal cord and dorsal root 
ganglia. By d34 there is intense expression in the CNS and expression in the otic 
vesicle is now restricted to the dorsal part. By d47expression is strong in the neural 
retina and rhombencephalon, moderate in the semicircular canals, forebrain, pituitary, 
olfactory bulbs and nerves. By 9 weeks it is expressed in the nasal epithelia, neural 
retina, optic nerve sheath and pituitary. 
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In this study I have confirmed that CHD7 is a cause of CHARGE syndrome by 
mapping the breakpoints of a balanced translocation in twin girls affected by 
CHARGE syndrome. The breakpoint on chromosome 8 disrupted CHD7 between 
exons 3 and 8. Sequence analysis of a cohort of 45 individuals with clinical features 
suggesting a possible diagnosis of CHARGE syndrome identified a pathogenic 
mutation in 28 of the 43 in which analysis was successful, a detection rate of 65%. 
When clinical diagnostic criteria are applied to this cohort we identified a mutation in 
28/34 (82%) of individuals who had at least atypical CHARGE syndrome. The 
majority of the mutations are predicted to cause truncation of the protein (nonsense and 
frameshift mutations, 26/28 (93%), there were two splice site mutations, one causing a 
deletion of exon 11 resulting in a frameshift and premature stop codon, the other 
causing insertion of 15 base pairs in frame. Two missense sequence changes of 
uncertain significance were also identified. In 7 of our families we were able to 
confirm that the mutations were de novo. Parental samples were not available from the 
remaining 21.The mutations were spread throughout the gene with no mutation 
hotspots. 20 of the 28 mutations were novel, previously unreported mutations. 8 of the 
mutations had been previously reported by other groups carrying out mutation analysis 
of affected individuals. As with this study they have found mutations throughout the 
gene. Most mutations are unique with the exception of R1339X, R1819X, W2332X, 
R2653X(Lalani et al., 2005)W1994X, R2050X(Jongmans et al., 2006), R2284X, 
I1028V,R1069X,D1596G,R1820X,R2319C(Vourela et al., 2007), R494X, R947X, 
Q1214R, R1810X(Wincent et al.,2008). In this study R2627X, R1219X, R1819X, 
Y835X, 5405-17G>A, R2418X, R2653X and R1339X were the mutations which had 
been reported before. In most studies no genotype/phenotype correlations have been 
found (Aramaki et al., 2006; Jongmans et al., 2006). However Lalani et al (2005) 
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found a correlation between the presence of a mutation and cardiovascular 
malformation, coloboma and facial asymmetry (Lalani et al., 2005). When diagnostic 
criteria are applied to the individuals being tested for mutations the positive predictive 
value of the clinical diagnostic criteria (Blake et al., 1998) is 95% (Jongmans et al., 
2006). In our cohort the positive predictive value of using Blake’s diagnostic criteria is 
85% which is comparable with that of Jongmans. Table 12 shows the percentage of 
individuals with each of the more common clinical features in four recently reported 
studies and in this study. 
 
Table 12. Comparison of clinical features with the presence of a mutation in four recent studies. 
 Aramaki 2006 Lalani 2005 Jongmans 2006 Wincent 2008 Current study average 
No. Sequenced 24 110 107 30 43  
No. with mutation 17(71%) 64(58%) 69(65%) 20(66%) 28(65%)  
Semicircular canal/cochlea 
hypoplasia 
6/6(100%) 21/22(95%) 21/21(100%)a 8/9(89%) 5/5 (100%) 97% 
Coloboma 15/17(88%) 55/62(89%) 33/47(70%) 18/20(90%) 24/28(86%) 83% 
Microphthalmia - - 10/47(21%) -   
Congenital heart disease 13/17(76%) 54/59(92%) 31/47(66%) 15/20(75%) 22/28(79%) 79% 
Choanal atresia/stenosis 5/17(29%) 34/57(60%) 17/47(36%) 8/20(40%) 7/27(26%) 42% 
Cleft lip/palate 8/17(47%) 18/60(30%) 17/47(36%) 4/20(20%) 11/28(39%) 34% 
Developmental delay 17/17(100%) - 24/32(75%) 11/15(73%) 23/23(100%) 86% 
Postnatal growth retardation 14/17(82%) - 21/32(63%) 17/19(89%) 22/27((81%) 78% 
Genital hypoplasia 
/gonadotrophin deficiency 
13/17(76%) 29/53(55%) 13/15(87%) 12/20(60%) 15/27(56%) 62% 
External ear abnormality 17/17(100%) 59/62(95%) 47/47(100%) 18/20(90%) 24/28(86%) 95% 
Hearing loss - 54/59(92%) 37/41(90%) 14/15(93%) 22/27(81%) 89% 
Facial asymmetry - 36/56(64%) 10/47(21%) 9/19(47%) 13/27(48%) 46% 
Laryngomalacia 14/17(82%) - 1 
tracheomalacia 
- 3/28(11%)  
TOF 3/17(18%) 10/55(18%) 8/47(17%) - 6/28(21%) 18% 
a. only 21 individuals had MRI scans.27/41(57%) showed evidence of vestibular 
anomaly. 
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Face 
The facial appearance of patients with CHARGE syndrome is square shaped with 
bitemporal narrowing. The nasal bridge is wide, the mouth is small with down turned 
corners of the upper lip (Blake et al., 1998 and see photographs in case reports, 
appendix II). Abnormalities of the ear and cranial nerve palsies cause facial 
asymmetry. Cleft lip and palate may also contribute to the dysmorphic features. 
 
 Ear abnormalities/hearing loss 
Most patients with CHARGE syndrome have hearing loss. This may be conductive, 
sensorineural or mixed loss. It may also be progressive. In our cohort 81% of mutation 
positive cases had hearing loss. This was a slightly lower percentage than in the other 
mutation studies (90-93%). (Lalani et al., 2005; Jongmans et al., 2006; Wincent et al., 
2008) 
 It is important that hearing loss is treated with hearing aids/ cochlear implants to 
maximize the communication abilities. CT abnormalities found in people with 
CHARGE include ossicular malformations, abnormal/absent semicircular canals, 
malformation of the pars superior and inferior, mondini deformity, absence of the oval 
window and stapedius muscle, narrow bony internal auditory canals, venous 
malformations and aberrant course of the facial nerve (Lemmerling et al., 1998; Satar 
et al., 2003; Stjernholm et al., 2003). However Cochlear implants have been shown to 
be successful in people with CHARGE (Woolley et al., 1998; Papsin, 2005; Lanson et 
al., 2007) although it is especially important to do a proper evaluation of the vascular 
system in the area. A recent report by Song et al (2008) described a case with a skull 
base vascular anomaly with an enlarged collateral emissary vein superficial to the 
mastoid area which was draining the internal jugular veins. 
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Semicircular canal abnormalities are found in nearly all individuals with CHARGE 
who have a mutation. Only 5 mutation positive cases in our cohort had had temporal 
bone imaging. All 5 had semicircular canal hypoplasia which supports the finding in 
other studies. Semicircular canal abnormalities are now included in the major 
diagnostic criteria for CHARGE syndrome which would suggest that temporal bone 
imaging should be performed in all individuals in whom this diagnosis is being 
considered. However it is important to liaise closely with the radiologists when 
requesting this investigation or abnormalities may be missed. One of our cases, KW 
was initially reported as having abnormalities of the malleus and incus and normal 
semicircular canals. A review of the scans was requested and it was noted that she had 
rudimentary superior semicircular canals with absent lateral and posterior semicircular 
canals. 
 
Coloboma 
 Coloboma with or without microphthalmia occurs in 70-90% of cases.( Lalani et al., 
2005; Aramaki et al., 2006; Jongmans et al., 2006; Wincent et al., 2008) 
They may be unilateral or bilateral. They may be small and as only a small proportion 
involves the iris it is important to arrange formal fundoscopy in patients in whom the 
diagnosis of CHARGE syndrome is a possibility. The percentage of individuals with 
coloboma in our cohort was concordant with that found in the other studies. There was 
no significant difference in the frequency of coloboma in our mutation positive cases 
(24/28, 86%) compared with the mutation negative cases who met the diagnostic 
criteria (5/6, 83%). As with other studies the majority of our cases had bilateral 
coloboma. Other abnormalities in the eye include hypoplasia of the optic nerve, 
anophthalmia and refractive errors. These structural problems cause defects in vision 
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which may result in strabismus and nystagmus. Atresia of the lacrimal ducts, eyelid 
coloboma and ankyloblepharon have also been reported (Tellier et al., 1998; Chestler 
and France, 1988; Blake et al., 1990). Vision in CHARGE syndrome ranges from 
normal in the majority to blindness. 
 
Congenital heart disease 
Congenital heart disease was present in 66-92% of those with a mutation (Lalani et al., 
2005; Jongmans et al., 2006; Aramaki et al., 2006; Wincent et al., 2008). In our study 
79% of cases with a mutation had congenital heart disease (22/28) compared to 66 % 
(4/6) of the mutation negative cases who met diagnostic criteria. The most common 
malformation was a PDA alone or in combination with another defect. Tetralogy of 
fallot was less common in our series than in other studies with a frequency of 4% in 
comparison to 33% (Cyran et al., 1987; Tellier et al., 1998). AVSD, PAVD and 
DORV also occurred at a frequency of 4%. 
 
Choanal atresia.  
Choanal atresia/stenosis is present in 29-60% of those with a mutation (Lalani et al., 
2005; Jongmans et al., 2006; Aramaki et al., 2006; Wincent et al., 2008). In our study 
26 % (7/27) of cases with a mutation had choanal atresia/stenosis compared to 66% 
(4/6) of the mutation negative cases who met diagnostic criteria. Choanal atresia is 
usually of the bilateral osseous type (Sanlaville and Verloes, 2007), but may be 
membranous and unilateral. In our cohort it was unilateral in at least 43% of cases, 
although the figures are small with only 7 affected individuals. There may be a bias in 
reporting bilateral atresia unless imaging of the choanae is performed in all cases with 
CHARGE as unilateral atresia may be asymptomatic. 
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Orofacial cleft 
Orofacial clefts were present in 20-47% of those with a mutation (Lalani et al., 2005; 
Jongmans et al., 2006; Aramaki et al., 2006; Wincent et al., 2008). In our cohort 39% 
(11/28) of cases with a mutation had orofacial clefting compared 0% (0/6) of the 
mutation negative group. 
 
Developmental delay 
Development in people with CHARGE may range from near normal to profound 
retardation. In the mutation studies delay was found in 75-100% of those with a 
mutation (Jongmans et al., 2006; Aramaki et al., 2006; Wincent et al., 2008). Our 
study produced similar figures with delay in100% (23/23) of individuals for whom this 
information was complete. 
 
Growth retardation 
Most patients with CHARGE syndrome have a normal birth weight. Post natal growth 
retardation is common. There are many interacting factors which may cause growth 
retardation. Cardiovascular, respiratory and feeding problems may all contribute. There 
is also growth hormone deficiency in some cases. Growth retardation was found in 63-
89% of cases with a mutation (Jongmans et al., 2006; Aramaki et al., 2006; Wincent et 
al., 2008). In our cohort 81% (22/27) of the children were growth retarded which is 
concurrent with the other studies. People with CHARGE syndrome can continue to 
grow in height well into their twenties (Blake et al., 2006). 
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Genital hypoplasia/hypogonadism 
Genital hypoplasia with or without hypogonadism occurs in 55-87% of mutation 
positive individuals (Lalani et al., 2005; Jongmans et al., 2006; Aramaki et al., 2006; 
Wincent et al.,2008). It was found/reported in 56% (15/27) of our cohort which is 
towards the lower end of this range. 78% (11/14) boys and 44% (4/9) girls had genital 
hypoplasia. Genital hypoplasia is more difficult to identify in girls and this can lead to 
under reporting. Accurate data for the frequency of hypogonadism is also difficult to 
obtain as despite short stature and genital hypoplasia many people with CHARGE 
syndrome do not routinely have endocrine investigations at present. 
 
Cranial nerves 
Cranial nerve abnormalities now form one of the major diagnostic criteria for 
CHARGE syndrome. Reviews of the cranial nerve abnormalities which occur in 
CHARGE by Byerly et al (1993) showed that abnormities of the seventh, eighth and 
ninth/tenth nerves were common whilst the third and sixth nerves were only 
occasionally involved. Tellier et al (1998) stated that 78% of patients had cranial nerve 
dysfunction affecting at least one nerve, usually the seventh and eighth. Examining the 
data more closely from these and other studies the seventh nerve is involved in 32-48% 
of cases (Blake et al., 1990; Byerly et al., 1993; Edwards et al., 1995,2002; Hartshorne 
et al., 2005; Stromland et al., 2005; Tellier et al., 1998). The figures in our cohort are 
consistent with this as 48% of individuals had a seventh nerve palsy. 
The eighth nerve is involved in 49-68% of cases (Blake et al., 1990; Byerly et al., 
1993; Edwards et al., 1995, 2002; Tellier et al., 1998). In our cohort 81% had 
sensorineural or mixed hearing loss. These were individuals in whom we had identified 
a mutation. The previously quoted studies predated the availability of mutation 
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analysis and may represent a more heterogeneous diagnostic group. The percentage of 
individuals with hearing loss reported in the studies where mutation analysis has been 
carried out show that 90-93% are affected, although these do not distinguish between 
those with sensori neural and those with conductive hearing loss (Lalani et al.,2005; 
Jongmans et al., 2006; Wincent et al.,2008). 
Previous reports indicated that the ninth/tenth cranial nerves are affected in 31-79% of 
cases (Byerly et al., 1993; Hartshorne et al., 2005). In our cohort 48%(13/27) mutation 
positive cases had swallowing problems indicating involvement of the ninth/tenth 
nerves. 
As cranial nerve abnormalities are now recognized as a major features in CHARGE 
Blake et al (2008) carried out a study to look specifically at cranial nerve abnormalities  
five, seven, eight and nine/ten (Blake et al.,2008). They  reported that 92% of cases 
had at least one cranial nerve involved, 72% of cases had more than one nerve 
involved and 18% had all four cranial nerves involved. It is postulated that these nerves 
may be affected more frequently than the other cranial nerves as they are different 
from the other motor nerves in that they have associated sensory ganglions derived 
from the interaction of the neural crest mesenchyme and ectodermal placodes. 
Abnormalities of the first cranial nerve causing olfactory deficits are thought to be 
common in CHARGE. Chalouli et al (2005) found olfactory deficits in 14/14 in the 
group they studied. In our cohort absent sense of smell was only reported in one case, 
JW, however many of our cases were too young or had too severe learning difficulties 
to enquire about problems with this sense. To date in the U.K. it has not been routine 
practice to perform scans of the arrhinenchephalon and olfactory bulbs in these 
patients. 
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Cranial nerves two, three, four and six are difficult to assess because of the 
confounding effects that coloboma and eighth nerve abnormalities cause. 
Abnormal function of the twelfth nerve has been anecdotally noted (Blake et al., 2008) 
but not previously reported in the medical literature. Our case JW has dysfunction of 
the first,sixth,seventh,eighth,ninth/tenth and twelfth cranial nerves representing the 
more extreme end of the spectrum. He also has cutaneous allodynia. Despite this he 
manages in a main stream school with support. 
Lalani et al (2005) found a correlation between the presence of a mutation and 
cardiovascular malformation, coloboma and facial asymmetry (Lalani et al., 2005). In 
our study cranial nerve palsy and orofacial cleft was positively associated with finding 
a mutation. Choanal atresia was more common in the mutation negative group. 
 
Feeding and breathing problems. 
Laryngomalacia is common in CHARGE affecting 8-37% of patients (Stack and Wyse, 
1991; Morgan et al., 1993; White et al., 2005). It is thought to be a common cause of 
upper airway obstruction. Laryngomalacia usually resolves spontaneously by 2 years. 
Between 10-22% (Friedman et al., 1990) will need surgery which usually has a 
successful outcome. However this is not always the case in children with CHARGE 
and this may be due to the presence of other causes of upper airway obstruction such as 
pharyngolaryngo hypotonia perhaps due to ninth and tenth cranial nerve palsies. Naito 
et al (2007) carried out a fiberoptic laryngoscopic study of 10 patients with CHARGE 
which showed that all the patients had structural abnormalities of the larynx, arytenoids 
and vocal cords. This is a further reason, in addition to the gastroesophageal reflux 
which occurs in 80% of patients that children with CHARGE are at risk from 
aspiration. The vocal cord abnormalities may be a contributory factor in the failure to 
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develop speech in some people with CHARGE. In one mutation study 14/17(82%) 
mutation positive children had laryngomalacia (Aramaki et al., 2006).In our cohort 
3/28(11%) of the children had laryngomalacia. It is possible that the discrepancy 
between these two figures is due to the lack of investigation rather than a true 
difference in the frequency of laryngomalacia. The complex feeding problems that 
occur in CHARGE means that 90% of the children will need tube feeding at some 
time. This may be prolonged. In the study by Dobbelsteyn et al (2007) of 39 children 
with CHARGE only half of the children were fed orally by the age of 5 years. One 
third of the children still had problems eating some food textures at age 
11(Dobbelsteyn et al., 2007). 
  
Tracheoesophageal fistula/oesophageal atresia 
Tracheoesophageal fistula/oesophageal atresia (TOF/OA) occurs in 1/3500 live births. 
In mutation studies 17-18% of cases have been found to have TOF/OA (Lalani et al., 
2005; Jongmans et al., 2006; Aramaki et al., 2006). In our study this malformation 
occurred with similar frequency. 21% (6/28) of cases had TOF/OA. 
 
Immune dysfunction 
Immunological abnormalities due to anomalies of the 3rd and 4th pharyngeal pouch 
complex causing absence or hypoplasia of the thymus and/or parathyroid glands may 
be under diagnosed in CHARGE syndrome. Writzl et al (2007) describe two patients 
with hypocalcaemia and a SCID phenotype. On reviewing the literature they found a 
further 12/15 individuals with CHARGE syndrome and an immunological abnormality 
with SCID. Salanville et al (2006) found that 7/10 abortuses with CHARGE had 
thymic abnormalities at post mortem. Sedlacek et al (2007) reports a further case of 
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CHARGE with SCID. In our cohort two individuals had a SCID phenotype (Gennery 
et al., 2008). More mild immunological abnormalities of T lymphocytes and humoral 
immunity also occur. Fuentes-Paez et al (2007) describe a case with hyper-
immunoglobulin M syndrome. Mild immunological abnormalities are likely to be 
under reported. Patients with CHARGE have other causes of frequent infections and 
therefore immune studies are frequently omitted.  
CHARGE syndrome is usually sporadic. However there have been a few reports of 
familial CHARGE syndrome and since the identification of the gene it has been 
possible to confirm this molecularly. Jongmans et al (2006, 2008) describe two 
affected brothers whose mother was found to be a somatic mosaic (Jongmans et al., 
2006), two sib pairs with apparently de novo mutations, a sib pair with mosaicism in 
the father who is unaffected and two families where the mother and child are affected 
(Jongmans et al., 2008). Delahaye et al (2007) describe two families. The first, two 
boys and their affected mother with a p.S834F missense mutation. The second family, 
two boys with clinical CHARGE syndrome and their father whose only abnormality 
was a cup shaped ear had p.R157X (Delahaye et al., 2007). Lalani et al (2006) report a 
pair of monozygotic twins, a de novo sib pair and an affected mother and daughter. The 
probands who led to this study were monozygotic twins with a balanced de novo 
translocation disrupting CHD7. As with the other familial cases the phenotype of 
different affected family members was not consistent. It is therefore not perhaps 
surprising that no genotype-phenotype correlations have been made in CHARGE 
syndrome. 
Whole gene/exon deletions are not common in CHARGE. To my knowledge they have 
only been reported on four occasions, two individuals by Vissers et al (2004) and one 
each by Arrington et al (2005) and Udaka et al (2007). 
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Limb anomalies 
Limb anomalies were not recognized initially as a significant part of the phenotype of 
CHARGE syndrome. There were occasional reports of limb anomalies as a rare finding 
but these were usually mild. Findings included a distal transverse crease which extends 
between the 2nd and 3rd finger web, 2-3 cutaneous syndactyly, tapered fingers, 5th 
finger clinodactyly and camptodactyly with absence of the distal phalanx of the 5th 
finger in one individual and nail hypoplasia, triphalangeal thumb and ectodactyly. 
There may be limited supination, talipes, sandal gap, tibial hemimelia and dimpling 
(Davenport et al., 1986; Oley et al., 1988; Meinecke et al., 1989; Prasad et al., 1997; 
Dhooge et al., 1998; Jongmans et al., 2006; Sanlaville et al., 2006). A report by Brock 
et al (2003) suggested that limb anomalies occurred in approximately 30% of patients 
with CHARGE. These were usually mild. However there have now been further papers 
reporting significant limb anomalies in individuals with mutations or deletions of 
CHD7.Tibial hypoplasia (Aramaki et al., 2006) bilateral ectrodactyly of the upper 
limbs (Sanlaville et al., 2006), bifid femora and fibula aplasia in a child with a 
presumed deletion of CHD7 (Asamoah et al., 2004) and three cases described by Van 
de Laar et al (2007). The first case had unilateral monodactyly and ulnar hypoplasia. 
The second case had bifid right femur, bilateral tibial aplasia, dysplastic fibular and 
four digits on each foot. The third case had tibial aplasia on the right and hypoplasia on 
the left. Our case CD adds to this spectrum of more severe anomalies. She has an 
absent radius in the left arm and only three digits in the hand. CHD 7 is expressed in 
the limb bud mesenchyme during embryogenesis (Sanlaville et al., 2006) and therefore 
abnormalities would be predicted to occur. The limited number of cases with 
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significant limb abnormalities reported to date might be explained by the failure to 
recognize CHARGE syndrome as a possible diagnosis in patients with these 
anomalies. Our case CD is an example of this, before review by the author it was 
thought unlikely that CHARGE was the correct diagnosis because of the presence of 
the limb anomaly. 
CHARGE syndrome remains a clinical diagnosis. It is likely that there are other genes 
involved although it is likely that CHD7 is the major gene as mutations have been 
identified in 85-95% of individuals who meet the diagnostic criteria (current study, 
Jongmans et al., 2006). The diagnosis of CHARGE syndrome cannot be excluded on 
the basis of negative analysis of CHD7. 
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Conclusion  
 
 
We have confirmed that mutations in CHD7 are the cause of CHARGE syndrome in 
the majority of cases who meet diagnostic criteria. The mutation detection rate in our 
cohort was 82%. 
There are no hotspots for mutations in CHD7 and no genotype/phenotype correlations 
have been identified. 
Coloboma, external ear anomalies, congenital heart defects, genital abnormalities, 
growth retardation, developmental delay and orofacial clefting were all present at 
higher frequencies in mutation positive cases, however the presence of a cranial nerve 
palsy was most positively associated with identifying a mutation.  
We would recommend that mutation analysis of CHD7 is worthwhile in any 
individuals with at least atypical CHARGE as defined by Verloes (2005) criteria. In 
addition these criteria should be used in preference to Blake’s as they are more 
inclusive allowing a diagnosis to be made in more patients. 
Imaging the semicircular canals and hormone studies should be performed in any 
individuals in whom the diagnosis of CHARGE syndrome is being considered both to 
aid in making the clinical diagnosis and to allow the appropriate treatment. 
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Further Work 
It would be interesting to do expression studies of CHD7 in the cases in our cohort 
who did not have a mutation in the gene, to ascertain whether they have 
reduced/altered expression of CHD7 or whether another gene was likely to be the 
underlying cause of their condition. 
Prospective studies of children with CHARGE syndrome looking at the management 
of their physical problems would be of value. This would include immunological 
studies in all children with a diagnosis of CHARGE syndrome which is probably an 
under recognized part of the phenotype.  In those with certain types of immune 
abnormality, treatment might reduce morbidity and the effect on intellect which occurs 
with hypoxemia related to frequent infections. Using this same rationale, congenital 
heart malformations should be aggressively treated, and those individuals with 
obstructive airway problems due to tracheobronchomalacia should be treated with 
CPAP. 
This might identify whether aggressive management or the lack thereof has a major 
effect on the intellectual outcome or whether the presence of a brain malformation is 
the only predictor of this. 
CHD7 is possibly at the top of a gene pathway and it will be fascinating in the future if 
the genes with which it interacts, and its relationship to other malformation syndromes 
can be elucidated. 
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 UCSC Human Genome Browsers, http://genome.ucsc.edu/cgi-bin/hgGateway 
Ensembl Human Genome Browser, http://www.ensembl.org/ 
CHORI BACPAC Resources, http://www.chori.org/bacpac/ 
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Appendices 
 
Appendix I. Details of the primers, fragment sizes and the annealing 
conditions used in DNA amplification 
 
Exon Exon 
Size(bp) 
Forward primer 5’-3’ Reverse primer 5’-3’ Amplicon 
size(bp) 
Fra Annealing 
temp oC 
2A gagggcaaacacctcagtgaagt ctgctgtccacaaaggattgcc 503 1 60 
2B tggcagtggtggcggtca ctgtctggctccgagaactaaagtta 548 2 65+DMSO 
2C gttgcccacagtcccagattct ctgctggcagtttctggggcc 567 3 65+DMSO 
2D 
1839 
gggataccaatggaagttggc gcacaatccctgggacaggg 596 4 60 
3 431 gaaacatcagccactaactttca cccctcatttcataggctgta 599 5 53 
4 142 gcattttgcacaaatgtactatgtgtgg ggggaggtcttgtgtacttcatacatgg 485 6 54 
5 138 gccactgtcttgggtttttg ccaacattaggtggatgttcc 290 7 54 
6 66 cagtgacttaaaaggtgtggaggtgg ttagacaggattagaaatattactggaag 308 8 54 
7 56 ccaaatttggggtcaggttgttgtg atacacagaagttagtcaacttttacacc 568 9 54 
8 115 gctcagcagccttaatgggtaattaag
c 
gttaccaatatgcaagttgacagcac 374 10 54 
9 84 gccaaatgtaagttttatattgc gctctgaccaagaccaggtc 302 11 60 
9  aacttttttttttccctttg internal    
10 138 gagcatgcttttccttaatgtg ctccctggaactctccgatt 579 12 60 
11 122 atcgaggagtttgagaaactaatg acacacttatatcaatctctgtattaat 449 13 60 
12 244 tttgggtatgcatttgtgggtacaatgg ccttcccaagtcaccaagac 436 14 60 
13 177 ataacttgaaaacagaatgtatgtcacc ccagagaatatatcacaatatttgacaagc 452 15 60 
14 144 cctgattcctatactttgcatagggtag ggtgggaaaaactgtaatataatcacac 382 16 54 
15 256 tggatgtttaatgaatgagataatcctg aggaatgactatacaccatgaaatcc 483 17 54 
16 211 attcttgttcataagcaggagtttggtg ttttaggtggactgcttggacccc 418 18 54 
17 196 cgccaataaaccctatttgct cgcaacattaatttatgggtctgactgg 446 19 60 
18 168 taccatcacattggaatgag ggctgagtaatttcttactattagtta 346 20 60 
19 180 tgcagcatttgtttagtctgc attcccaatgcatcttgtaagc 352 21 60 
20-21 111,206 cggagcaaatacataaacaaaa ggggtgtcacacaaattcaa 600 22 53 
22 200 ctggtacctgacttaaagtaaagc ccccttggcacaggagc 418 23 60 
23 160 tgctacagggtcacaaagc gttgaccctccaaatctgc 439 24 60 
24 90 caggatgatggatgaacagc cgaaggacaaatactgcattc 330 25 60 
25 104 atgtttatcgtgggagagag gagtcctttggaactatcctc 319 26 60 
26 130 gttgtggcagtgctgtgatt tgtgtactgcagggtaagaactg 300 27 60 
27-28 73,63 agattattactctttcctacccacccc ccacgtgaacaatgactgctcagtgcac 437 28 54 
29 224 ccctttcccacactgtcatt gagcctttctttggtggtca 455 29 53 
30 209 ccacccccaaataactacca tctgtaacacagaagggctca 443 30 55 
31A aacaaagttctatacaaaaagacgag ccagtgggttcaaggaag 443 31 60 
31B 
672 
ggttggtgctgctaaacacg ccgtgctgccagaaagc 549 32 60 
32 161 ccatgtagtaggtactcaataaaatgg
agc 
caagctagaaagatttcctctaccctaatc 355 33 60 
33 228 cattttatgctcttttgcatcttgatgg gggctggcttttagaaataaggaaca 509 34 60 
34 444 tgttccttatttctaaaagccagccc ggctttcatacaatgctgctgagagaaac 636 35 60 
35 222 gttcccaaacaactagacattgtttcta
g 
ctgtcagggatttctatgttgtaagg 451 36 54 
36-37 141,105 ttgaagatgatctgacagttctctttgg gatgtattatgtcaattcttttaagctaag 678 37 54 
38A gttcaccacagaggctcacattgagat
c 
tcgtcttcattctcatttcc 562 38 53 
38B 
1889 
 
aggagaaccggaagacag gcactgcacaatacttaatgac 685 39 53 
 
NB 9Fseq aacttttttttttccctttg 
 
 
